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Abstract
The peroxisome proliferator-activated receptor alpha (PPAR?) is a ligand-activated transcription factor
involved  in  the  regulation  of  a  variety  of  processes,  ranging  from inflammation  and immunity  to
nutrient metabolism and energy homeostasis. PPAR? serves as a molecular  target for hypolipidemic
fibrates drugs which bind the receptor with high affinity. Furthermore, PPAR? binds and is activated by
numerous fatty acids and fatty acid-derived compounds. PPAR? governs biological processes by altering
the expression of a large number of target genes. Accordingly, the specific role of PPAR? is directly
related to the biological function of its target genes. Here, we present an overview of the involvement
of PPAR? in lipid metabolism and other pathways through a detailed analysis of the different known or
putative PPAR? target genes. The emphasis is on gene regulation by PPAR? in liver although many of
the results likely apply to other organs and tissues as well.
1. Introduction
Nutrient metabolism and energy homeostasis are tightly controlled by numerous regulatory systems
involving specific  transcription  factors.  The  peroxisome  proliferator-activated receptors  (PPARs)  are
ligand-activated transcription factors that belong to the superfamily of nuclear hormone receptors and
play  an  important  role  in  nutrient  homeostasis  [1–3].  Three  different  PPAR  subtypes  are  known:
P P A R ? ,  P P A R ? / ? ,  and P P A R ? .  All  PPARs share the same molecular mode of action via formation of
heterodimers with the nuclear receptor RXR, followed by binding to specific DNA-response elements in
target genes known as peroxisome proliferator response elements (PPREs). PPREs are characterized by
a common core sequence consisting of a direct repeat of the consensus sequence AGGTCA interspaced
by a single nucleotide [1, 4]. Expression of P P A R ?  and PPAR?/? is found ubiquitously, whereas PPAR?
is mainly expressed in adipose tissue, macrophages, and colon [5, 6]. Activation of transcription by
PPARs is dependent on a number of different steps including ligand binding to PPAR, binding of PPAR to
the target gene, removal of corepressors and recruitment of coactivators, remodeling of the chromatin
structure, and finally facilitation of gene transcription [7]. This paper will focus exclusively on PPAR?.  
P P A R ?  was first  discovered in  the  early  1990s and since  then  has been  identified as  the  master
regulator  of  hepatic  lipid  metabolism [8].  In  addition,  PPAR?  has  been  shown  to  govern  glucose
metabolism,  lipoprotein  metabolism,  liver  inflammation,  amino  acid  metabolism,  and  hepatocyte
proliferation (specifically in rodents). Synthetic agonists of PPAR?  lower plasma triglycerides and raise
plasma  high-density  lipoprotein  (HDL)  levels  and  are  thus  used  clinically  in  the  treatment  of
dyslipidemia [2, 9–11].
In  recent  years,  the  advent  of  microarray  technology  has  allowed  the  study  of  whole  genome
expression profiles. Accordingly, a wealth of new information has become available about the role of
specific transcription factors in regulation of gene expression. Combined with data collected using more
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established methods, microarray has permitted the generation of a comprehensive picture of the impact
of P P A R ?  on gene expression, thereby providing key insight into the functional role of PPAR?. The
present paper is aimed at providing a detailed and updated overview of PPAR? target genes in different
biological processes and to highlight possible differences between mouse and human.
Although the presence of a functional PPRE is often used as a criteria for designating direct PPAR?
target genes, we did not apply this criteria very stringently in our analysis as the in vivo functionality
of most of the identified PPREs remains uncertain. Recent studies indicate that the standard approach
to screen for PPREs in the 1-2 kb region upstream of the transcriptional start site (TSS) is at odds with
accumulating evidence  that  PPARs often  bind quite  distant  from the  TSS  [12–14].  In  those  cases,
contact with the basal transcription machinery is expected to be established via DNA looping. Thus, the
absence of a PPRE in the 1-2 kb region upstream of the TSS cannot be used as a criterion to disqualify
target genes. Other aspects that need to be taken into account include correspondence in gene function
with better established PPAR targets and the timing of gene induction following PPAR? activation.
2. PPAR? Tissue Expression Profile in Mouse and Human
High expression levels of P P A R ?  expression are found in liver and specifically in the parenchymal cell
population. Expression of P P A R ? in nonparenchymal liver cells such as Kupffer cells is much lower [15,
16].  Other  tissues with  high  P P A R?  mRNA  levels  are  heart,  kidney,  intestine,  and brown  adipose
tissue,  all  of  which  are  characterized  by  an  elevated  rate  of  fatty  acid  catabolism  [17].  PPAR?
expression  has also been  detected in  immune  cells such  as the  peripheral  blood mononuclear  cell
population,  and specifically  in  T-cells  and macrophages [18–22].  Evidence  suggests  that  mice  and
humans share similar P P A R ?  tissue expression profiles [6, 17] (Figure 1). In the past, the importance
of P P A R ?  in human liver was questioned based on data showing approximately 10-fold lower PPAR?
mRNA levels in  human liver  compared with  mouse liver  [23]. A recent study using more advanced
methodology revealed similar P P A R ?  expression in mouse and human liver and in mouse and human
hepatocytes,  thus  strongly  arguing  against  this  notion  [24].  Given  that  PPAR?  has  been  most
extensively studied in liver, most of the information on PPAR?  target genes presented here relates to
hepatic gene regulation.
Figure 1: Expression profile of ? ? ? ??  in human tissues. The FirstChoice Human
Total RNA Survey Panel (Ambion) was reverse transcribed and used for qPCR using
primers  specific  for  human  PPARα.  Expression  levels  are  expressed relative  to
small intestine, which showed the highest expression level (100%).
3. PPARα Structure in Mouse and Human
Analogous to other nuclear receptor superfamily members, PPAR?  has a domain structure consisting of
an  N-terminal  activating  function-1  (AF-1)  domain,  a  central  DNA-binding  domain  (DBD),  and  a
C-terminal  ligand-binding  domain  (LBD)  [25,  26].  The  N-terminal  domain  can  be  phosphorylated
leading to changes in transcriptional activity and even ligand binding of the receptor [27]. The DBD is
responsible  for  physical  interaction  with  DNA  and  allows  PPAR?  to  bind  to  specific  PPREs  as  a
heterodimer with RXR [28]. The LBD harbors the ligand-binding pocket crucial  for dimerization with
RXR and contains the activating function-2 involved in physical interactions with coregulatory proteins
[7, 29, 30]. Comparison of human and murine P P A R ?  shows 85% identity at the nucleotide level and
91% identity at the amino acid level. Data have indicated that there is some genetic heterogeneity in
the functional coding sequence of human P P A R ?  that translates into functional differences in receptor
activity. One identified variant of the human P P A R ? gene produces a protein that is mutated within the
P P A R ?  DNA-binding  domain.  This  L162V  gene  variant  exhibits  greater  ligand-induced  activity
compared to the wild-type receptor  [31, 32]. While  there is some evidence for  a link between the
L162V polymorphism and metabolic parameters such as plasma lipid levels, these correlations are not
always found [32–37].  Interestingly,  the  effect  of  L162V  polymorphism has been  suggested to  be
modulated via gene-drug and gene-nutrient interactions [38–40]. The V227A polymorphism was found
in Japanese population and has been associated with altered serum lipid levels and nonalcoholic fatty
liver disease [41–44]. In addition to polymorphic variants, a truncated splice variant of human PPAR?
has been described that negatively interferes with wild-type PPAR? activity [45].
4. PPARα Ligands
P P A R ?  serves as receptor  for  a structurally diverse set of compounds. The most important class of
synthetic P P A R ?  ligands is the fibrates, including gemfibrozil, bezafibrate, clofibrate, fenofibrate, and
Wy14643  [2,  9–11,  46].  This  class  of  drugs  is  used  in  the  treatment  of  dyslipidemia  primarily
associated with type 2 diabetes mellitus. In addition, PPAR?  is activated by plasticizers, insecticides,
and other rodent hepatic carcinogens. Natural ligands of PPAR?  include a variety of fatty acids as well
as  numerous  fatty  acid  derivatives  and compounds  showing  structural  resemblance  to  fatty  acids,
including acyl-CoAs, oxidized fatty acids, eicosanoids, endocannabinoids, and phytanic acid [47–53].
Endogenous ligand activation of P P AR? in liver was initially suggested to occur primarily during fasting
as large amounts of free fatty acids are released into the bloodstream and enter the liver [54, 55].
However, compelling evidence indicates that hepatic P P AR?  is not activated by plasma free fatty acids,
whereas it can be activated by dietary fatty acids and fatty acids generated via de novo lipogenesis
[56–60]. Recently, it  was shown that the effects of dietary unsaturated fatty acids on hepatic gene
expression  are  almost  exclusively  mediated  by  P P A R?  and  mimic  the  effect  of  synthetic  PPAR?
agonists [61].
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5. PPAR? and Hepatic Lipid Metabolism
Regulation of lipid metabolism is mainly coordinated by liver, which actively metabolizes fatty acids as
fuel  and continuously produces very low-density lipoproteins (VLDLs) particles to provide a constant
supply of fatty acids to peripheral  tissues. Disturbances in these pathways are the basis for hepatic
steatosis and alterations in  plasma lipoprotein  levels. Many aspects of  hepatic lipid metabolism are
under  control  of  P P A R ? ,  including  fatty  acid  uptake  through  membranes,  fatty  acid  activation,
intracellular  fatty acid trafficking, fatty acid oxidation and ketogenesis, and triglyceride storage and
lipolysis (Figure 2). It has been suggested that part of the effect of PPAR?  on hepatic ketogenesis may
be  mediated  by  induction  of  the  PP A R ?  target  fibroblast  growth  factor  21  [90–92].  A  detailed
discussion of the specific genes within the various lipid metabolic pathways that are targeted by PPAR?
is provided below (Table 1).
Table  1:  List  of  ?? ? ? ?  target  genes  in  different  biological  processes  in  liver.
Genes regulated by ? ? ? ? ? in mouse are shown in lower case. Genes regulated in
human and mouse are shown in CAPITAL BOLD. Genes regulated only in human
are shown in CAPITAL, and genes with detected functional PPRE are shown in italic
font.
Figure 2: Schematic representation of PPAR?  target genes in different aspects of
hepatic lipid metabolism.
5.1. Peroxisomal Fatty Acid ?-Oxidation
The first link between P P A R ?  and fatty acid catabolism was established by the identification of the
Acyl-CoA  oxidase  gene,  encoding  the  rate-limiting  enzyme  in  peroxisomal  long-chain  fatty  acid
oxidation, as a direct P P A R ?  target gene [98, 172]. Peroxisomes are known to be involved in many
aspects of lipid metabolism, including synthesis of bile acids and plasmalogens, synthesis of cholesterol
and isoprenoids, alpha-oxidation, glyoxylate and H 2 O 2  metabolism, and beta-oxidation of very-long-
straight-chain or branched-chain acyl-CoAs. The beta-oxidation of straight-chain acyl-CoAs starts with a
reaction catalyzed by acyl-CoA oxidase 1 (Acox1) followed by one of two enzymes carrying both enoyl-
CoA-hydratase  and  3-hydroxyacyl-CoA  dehydrogenase  activity  (L-bifunctional  enzyme,  Ehhadh;
D-bifunctional  enzyme, Hsd17b4) and finally peroxisomal  3-ketoacyl-CoA thiolase (Acaa1a, Acaa1b).
All  genes mentioned above  represent  P P A R ?  targets [24,  55, 62, 68,  70,  76,  98, 99, 101–104].
Additionally, genes involved in peroxisomal fatty acid uptake (Abcd2 and Abcd3), conversion of fatty
acid to acyl-CoA (Crot), and numerous thioesterases (Acots) that convert acyl-CoAs back to fatty acids
have  been  reported  to  be  regulated  by  P P A R ?  [24,  62,  74,  96,  97].  Activation  of  PPAR?  using
synthetic agonists is known to cause massive proliferation of peroxisomes in rodents via induction of a
large set of genes encoding peroxisomal  fatty acid oxidation enzymes, as well  as genes involved in
peroxisomal biogenesis (Pex genes). Chronic exposure to these so-called peroxisome proliferators can
also induce liver cancer in rodents [173]. In contrast, activation of PPAR?  in humans does not seem to
induce hepatocellular carcinomas, suggesting a species specific response to PPAR?  activation. Initially,
it  was  believed  that  the  differential  response  was  due  to  the  lack  activation  of  Acox1  and other
peroxisomal genes by P P A R ?  in humans [71, 174, 175]. However, recent data indicate that PPAR?  is
able to induce a significant number of genes involved in peroxisomal  fatty acid oxidation in  human
primary  hepatocytes,  including  Acox1  [24].  Also,  P PAR?-mediated  induction  of  the  Pex11a  gene
involved in peroxisome proliferation is observed in both species [24].
5.2. Mitochondrial Fatty Acid ?-Oxidation
The crucial role of P P A R ?  in mitochondrial fatty acid oxidation is illustrated by the phenotype of fasted
P P A R ? − / −  mice, which exhibit hypoketonemia, hepatic steatosis, and elevated plasma free fatty acid
levels  [54,  55,  176].  It  is  now evident  that  virtually  every  enzymatic  step  within  the  fatty  acid
oxidative pathway is under control of P P A R ? .  Specifically, PPAR?  induces genes controlling fatty acid
import into the mitochondria (Cpt1, Cpt2, Slc25a20, Slc22a5), as well as the major enzymes within the
?-oxidation  pathway,  including  various  acyl-CoA  dehydrogenases  (Acad,  step  1),  mitochondrial
trifunctional enzyme (Hadh, step 2–4), and genes involved in β-oxidation of unsaturated fatty acid (Dci,
Decr) [24, 54, 55, 62, 63, 65, 68, 70, 74, 76–86].
Additionally, synthesis of ketone bodies via mitochondrial HMG-CoA synthase (Hmgcs2) and HMG-CoA
lyase (Hmgcl) is governed by P P A R ?  [24, 62, 93–95], as is the expression of genes encoding electron
transferring flavoprotein and the corresponding dehydrogenase (Etfa, Etfb, Etfdh) [24, 62]. The latter
proteins mediate  the  transfer  of  electrons from Acyl-CoA  dehydrogenases to  the  membrane-bound
electron  transfer  flavoprotein  ubiquinone  oxidoreductase,  allowing  further  entry  into  the  oxidative
phosphorylation  pathway  [177,  178].  Finally,  P P A R ?  induces  uncoupling  proteins  Ucp2  and Ucp3,
which have been proposed to function as an outward transporter of nonesterified fatty acid anions from
the mitochondrial matrix [24, 62, 87–89].
5.3. Microsomal Fatty Acid ?-Hydroxylation
Cyp4A  enzymes  are  members  of  the  cytochrome  P450  monoxygenase  superfamily  and  catalyze
microsomal ?-hydroxylation of fatty acids [106, 179]. Studies using PPAR?− /−  mice have shown that
hepatic expression  of Cyp4a genes is almost  completely  dependent on  PPAR?  (Cyp4a10, Cyp4a12,
Cyp4a14 in mice, Cyp4a1, Cyp4a3 in rat, Cyp4a11 in human) [55, 62, 74, 84, 106–111]. Furthermore,
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expression is extremely sensitive to PP A R ? ligand activation, indicating that Cyp4a genes may serve as
P P A R ?  marker genes. Although previous studies performed in human primary hepatocytes could not
show regulation  of  Cyp4a  by  human  P P A R ? ,  our  microarray  data  revealed significant  induction  of
Cyp4a11 by Wy14643 in primary human hepatocytes [24, 68, 180, 181]. ?-hydroxylation of saturated
and unsaturated  fatty  acids  may  lead  to  the  generation  of  high-affinity  PPAR?  ligands,  including
hydroxyeicosatetraenoic  acids  (HETEs),  thus creating a  positive  feedback  loop [182].  Alternatively,
induction  of  ?-oxidation  by  P P A R ?  has been  suggested to promote the  degradation  of  the  PPAR?
agonist  leukotriene  B4  as part  of  a  feedback  mechanism aimed at  controlling the  duration  of  the
inflammatory response [53].
5.4. Hepatic Lipogenesis
Whereas P P A R ?  is mostly known for its ability to induce fatty acid oxidation, growing evidence points
to a role of P P A R ?  in regulation of lipogenesis. A functional PPRE was identified in the promoter of a
limited  number  of  lipogenic  genes  including  Δ 6  desaturase  (Fads2),  malic  enzyme  (Mod1),
phosphatidate  phosphatase  (Lpin2),  and  Δ 9  desaturase  (Scd1)  [56,  115–117].  Gene  expression
profiling showed that chronic in vivo treatment of mice with PPARα agonist causes the upregulation of a
large set  of  lipid biosynthetic genes [62]. However, regulation  is much  less pronounced in  primary
hepatocytes,  suggesting an  indirect  mechanism. Consistent  with  this  notion,  induction  of  lipogenic
genes by chronic P P A R ?  activation was completely abolished in SREBP1− /−  mice [183]. The effect of
P P A R ? agonists on SREBP targets has been attributed to increased activation of SREBP1c via enhanced
proteolytic  cleavage  [112].  Such  a  mechanism may  also  lead  to  increased SREBP1  mRNA  via  an
autoloop regulatory circuit [184]. Alternatively, it is possible that PPAR?  is recruited to promoters of
SREBP targets and stimulates SREBP activity  [12]. Interestingly, in  rat  FAO hepatoma cells, it  was
found  that  P P A R ?  activation  reduced  expression  of  lipogenic  genes,  including  Fasn,  Gpam,  and
SREBP1c, while Insig1 expression was increased by P P AR? [185]. The reason for the discrepancy is not
clear.
In contrast to de novo fatty acid and cholesterol synthesis, synthesis of triglycerides may be directly
targeted  by  P P A R ? .  Several  genes  within  these  pathways  are  upregulated  by  PPAR?  activation,
including Gpam, various Agpat genes, Mogat1, Dgat1, and Lpin2 [24, 62, 65, 112]. Induction of genes
involved in triglyceride synthesis from fatty acids may reflect a broader role of PPAR?  in the hepatic
response to fasting aimed at neutralizing large amounts of incoming adipose tissue-derived free fatty
acids.
5.5. Fatty Acid Uptake and Binding
Before  they  can  be  metabolized  in  the  liver,  fatty  acids  have  to  be  transferred  across  the  cell
membrane.  Several  proteins  are  involved  in  fatty  acid  transport  across  the  plasma  membrane,  a
number  of  which  carry  both  fatty  acid  transporter  and acyl-CoA  synthetase  activity.  Studies  have
shown that the fatty acid transport proteins Slc27a1, Slc27a2, and Slc27a4 are upregulated by PPAR?
in liver [24, 62, 64–68, 101].
Slc27a1  is not  expressed and not  regulated by  P P A R ?  in  isolated primary hepatocytes, suggesting
regulation occurs in liver macrophages (Kupffer cells). So far, the only fatty acid transporter for which a
PPAR response element has been identified is Slc27a1. PPAR?  agonists also markedly induce hepatic
expression of the fatty acid transporter/scavenger receptor Cd36, which is expressed in various liver
cell types [24, 62–64]. Additionally, expression of numerous acyl-CoA synthetases is induced by PPAR?
[24, 62, 63, 70–73]. Currently, limited information is available about the cellular localization and the
structure/function relationship of acyl-CoA synthetase enzyme [186].
The  Fabp  gene  family  comprise  a  group  of  high-affinity  intracellular  fatty  acid-binding  proteins.
Interestingly, Fabp1 was one of the first  P P A R ?  target genes identified [74, 75, 187, 188]. Recent
studies indicate that Fabp1 may be involved in partitioning of FA to specific lipid metabolic pathways
[189]. Other Fabp genes induced by PP A R ? activation in mouse liver include Fabp2, Fabp3, Fabp4, and
Fabp5  [24, 62, 63].  Induction  of  Fabp4  (A-FABP, aP2) upon  PPAR?  activation  likely  occurs via  its
expression in Kupffer cells. Fabp4 expression in hepatocytes is correlated with acquisition of a steatotic
phenotype concurrent with upregulation of P P A R ? mRNA [190].
5.6. Lipases and Lipid Droplet Proteins
P P A R ? − / −  mice exhibit elevated hepatic TG accumulation, especially under fasting conditions [54, 191,
192]. Conversely, treatment with P PAR ? agonists lowers hepatic triglyceride levels in models of hepatic
steatosis and can prevent the fasting-induced increase in liver TG [193, 194]. The antisteatotic effect
of P P A R ?  has mainly been attributed to stimulation of fatty acid oxidation, which would decrease the
availability of fatty acids for TG storage.
Recently, hepatic lipid droplets were shown to be targeted by autophagy, which ultimately leads to TG
hydrolysis  via  lysosomal  acid  hydrolase  (Lipa).  Which  other  lipases  importantly  contribute  to
intracellular lipolysis of hepatic TG stores remains unclear, but lipases active in adipocytes likely play a
role, including Ces3, Lipe, Pnpla2, Mgll, and perhaps Pnpla3 [195–200]. With the exception of Pnpla3,
all of the above genes are induced by short-term treatment with PPAR?  agonist in mouse hepatocytes.
Regulation  of  Pnpla2  was  also  observed  in  human  hepatocytes.  Pnpla2  and  Lipe  were  previously
classified as direct target genes of PPA R ? in adipose tissue, suggesting that they are direct target of
P P A R ?  as well [201, 202]. Thus, apart from induction of fatty acid oxidation, PPAR?  activation may
also decrease hepatic TG storage by stimulating the TG hydrolysis pathway.
Lipid droplets are coated with one or more members of the perilipin family of proteins: perilipin (Plin1),
Adrp/adipophilin (Plin2), Tip47 (Plin3), S3-12 (Plin4), and Oxpat/Lsdp5 (Plin5). Adrp and Lsdp5 have
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been identified as target genes of PPA R ?  in liver [120, 124]. A recent study suggests that Adrp could
serve as potential mediator of the effect of P P A R ?  on VLDL production. Adrp induction by PPAR?  may
diminish VLDL production by favoring fatty acids storage in cytosolic lipid droplets rather than directing
through VLDL assembly [203]. Besides Adrp, expression of S3-12 and perilipin, which are known as
P P A R ? target genes in adipose tissue, is induced by P PAR?  agonist in human hepatocytes [24, 204].
Perilipin expression in human liver is correlated with development of steatotic liver [205].
Two recently identified lipid droplet-associated proteins that are not part of the perilipin  family  are
Cidec (FSp27) and Cidea [206, 207]. Both proteins promote TG accumulation and are targets of PPAR?
in  adipocytes [208, 209].  In  addition,  they  are  regulated by  PPAR?  in  mouse  liver,  although  the
kinetics  of  induction  of  the  two  genes  seems  to  be  quite  different  [121].  Cidec  but  not  Cidea
upregulation by P P A R ? agonist could be confirmed in human primary hepatocytes [24].
Interestingly, the G(0)/G(1) switch  gene 2 (G0s2) was recently  identified as an  inhibitor  of Pnpla2
activity and located to lipid droplets in adipocytes stimulated with ?-adrenergic receptor agonist [122].
Previously, G0s2 was shown to be a direct P P A R ?  target gene in mouse liver  and PPAR?  target in
adipocytes [123]. Whether  G0s2 associates with  lipid droplets in  hepatocytes remains to be further
investigated. Similar  to the induction  of triglyceride synthesis, regulation  of numerous lipid droplet
proteins  by  P P A R ?  reflects  a  broader  role  of  P P A R ?  in  the  hepatic  response  to  fasting aimed at
deflecting large amounts of incoming adipose tissue-derived free fatty acids towards storage in lipid
droplets.
6. PPAR? and Lipoprotein Metabolism
Clinical  studies in humans have provided ample evidence that fibrate drugs effectively lower fasting
plasma triglycerides (TG) and raise  plasma HDL [210–213]. At  the molecular  level, fibrates act  as
synthetic  agonist  for  P P A R ? ,  indicating  an  important  role  of  PPAR?  in  the  control  of  lipoprotein
metabolism.  P P A R ?  lowers  plasma  TG  in  part  by  reducing  very  low-density  lipoprotein  (VLDL)
production [194]. Traditionally, this effect of P P A R ? was ascribed to induction of genes involved in fatty
acid oxidation and the concomitant reduction in lipid availability for  VLDL production. However, this
paper  has made  it  evident  that  in  addition  to  its  role  in  fatty  acid  catabolism, PPAR?  influences
multiple aspects of intracellular lipid trafficking and metabolism, some of which may oppose hepatic TG
lowering. Furthermore, expression of Mttp, which is involved in the lipidation of apoB100 to form a
nascent  VLDL  particle,  is  positively  regulated  by  P PAR?  [214].  Thus,  the  precise  target  genes
underlying the suppressive effect  of  P P A R ?  agonist  on  hepatic VLDL production  remain  to be fully
elucidated.
In  addition  to  suppressing  VLDL  production,  P P A R ?  agonists  are  known  to  stimulate  clearance  of
TG-rich lipoproteins [194]. Clearance of TG-rich lipoproteins VLDL and chylomicrons is mediated by the
enzyme lipoprotein lipase (LPL), which is attached to the capillary endothelium of muscle and adipose
tissue. Expression of Lpl in liver is restricted to Kupffer cells and upregulated by PPAR?  agonists [140,
215]. In contrast, no evidence is available indicating a stimulatory effect of PPAR?  on Lpl expression in
heart and skeletal muscle, which account for the major share of plasma TG clearance [140, 216]. LPL
activity  is  mostly  regulated  posttranslationally  via  altered  secretion  from  liver  of  LPL-modulating
factors, including apolipoprotein C-III (Apoc3), apolipoprotein A-V (Apoa5), Angiopoietin-like protein 3
(Angptl3),  and  Angiopoietin-like  protein  4  (Angptl4).  Firstly,  PPAR?  agonists  downregulate  the
expression  of  LPL  inhibitor  APOC3,  supposedly  via  mechanisms  involving  the  transcription  factors
R E V - E R B ? ,  H N F 4 ? ,  or FOXO1 [137, 217–219]. Secondly, PPAR?  agonists increase hepatic expression
and plasma levels of APOA5, which is a positive regulator of LPL [220]. A functional PPAR responsive
element has been identified in the promoter of the human APOA5 gene, classifying APOA5 as a direct
P P A R ?  target gene [135, 136]. Thirdly, P P A R ?  upregulates hepatic expression and plasma levels of
Angptl4, which acts as inhibitor of LPL activity by converting active LPL dimers to inactive monomers
[126]. The DNA response element conferring PPAR regulation was located to intron 3 of the Angptl4
gene [127]. Finally, P P A R ?  stimulates hepatic expression of the VLDL receptor (Vldlr) [24, 62]. The
functional significance of Vldlr regulation in liver is unclear, as Vldlr is most highly expressed in adipose
tissue, heart, and skeletal  muscle, where it plays an auxiliary role in  plasma TG hydrolysis by LPL.
Recently, Vldlr was shown to be under control of P P A R ? in adipocytes [221]. Thus, it appears that both
pro- and antilipolytic pathways are activated by P P A R ?. Under conditions of pharmacological PPAR?
activation, the prolipolytic actions of P P A R ?  dominate, as illustrated by the stimulation of plasma TG
clearance.
P P A R ?  agonists raise plasma HDL levels in humans, which is most likely achieved via species specific
mRNA induction  of apolipoprotein  A-I (Apoa1) and A-II (Apoa2) [128, 175, 222–224]. Apoa1 gene
expression is not induced by P P A R ?  in rodents due to the presence of disabling mutations within the
PPAR-response  element  [129].  In  fact,  P P A R ?  activation  in  mouse  downregulates  Apoa1  mRNA
expression  and plasma concentrations through an  indirect  pathway involving the PPAR?-dependent
induction of the nuclear receptor R EV-E R B ? ,  a negative regulator of transcription [129, 130, 225].
The impact of P P A R ?  in HDL metabolism likely extends beyond regulation of apolipoproteins. Evidence
suggests that both P P A R ?  and P P A R? / ? stimulate expression of endothelial lipase (Lipg) in liver [62,
226]. Endothelial  lipase mainly  carries phospholipase  activity  and its overexpression  was shown  to
significantly reduce plasma HDL cholesterol  levels [227–229]. Since Lipg is expressed in endothelial
cells,  macrophages,  and  hepatocytes,  regulation  of  hepatic  Lipg  by  PPAR?  and  PPAR?/?  may  be
mediated  by  different  cell  types.  In  as  much  as  P PAR?  agonists  raise  plasma  HDL  levels,  the
physiological relevance of Lipg induction by P P A R ? remains to be established.
In  our  recent  publication,  the  P PAR ?  agonist  Wy14643  modestly  induced  hepatic  lipase  (Lipc)
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expression  in  primary  human  hepatocytes  [24].  Hepatic  lipase  exhibits  both  phospholipase  and
triglyceride hydrolase activity and hydrolyzes triglycerides and phospholipids of chylomicron remnants,
IDL, and HDL [230]. Whether Lipc represents a direct target gene of PPAR?  in human remains unclear.
Other  genes  involved  in  lipoprotein  metabolism  that  are  regulated  by  PPAR?  include
phosphatidylcholine transfer protein (Pctp). Induction of Pctp mRNA by PPAR?  is conserved in primary
human  hepatocytes  [24].  Pctp  encodes  a  steroidogenic  acute  regulatory-related  transfer  domain
protein that binds with high affinity to phosphatidylcholines. In a recent publication, a role for Pctp in
the  metabolic  response  to  P P A R ?  was proposed [231].  Overall,  it  is  evident  that  PPAR?  governs
multiple aspects of plasma lipoprotein metabolism.
7. PPAR? and Glucose/Glycerol Metabolism
Although  P P A R ?  has  mostly  been  linked  to  fatty  acid  metabolism,  studies  in  mice  have  yielded
considerable evidence for  a role of PP A R ?  in  hepatic glucose metabolism. Indeed, fasted PPAR?− /−
mice  display  severe  hypoglycemia  [54,  55,  176].  Several  mechanisms  may  account  for  the
hypoglycemia,  including  decreased  hepatic  glucose  production  and  increased  peripheral  glucose
utilization.  Genes involved in  gluconeogenesis that  have  been  identified as PPAR?  targets include
phosphoenolpyruvate carboxykinase (Pck1), pyruvate carboxylase (Pcx), and lactate dehydrogenase A
[62].  Interestingly,  regulation  of  Pck1  by  P P A R ?  was  only  observed  in  human  hepatocytes  [24].
Pyruvate carboxylase was identified as direct target of PPAR? in adipocytes [232].
P P A R ?  was shown to have a specific role in the metabolic conversion of glycerol in liver by directly
upregulating expression of genes such as Gpd1, Gpd2, Gyk, Aqp3, and Aqp9 [151]. Besides governing
glucose  production,  P P A R ?  may  also alter  glucose  utilization  in  numerous tissues via  induction  of
pyruvate  dehydrogenase  kinase  isoform 4  (Pdk4)  [153,  154,  233–236].  Pdk4  phosphorylates  and
inactivates  pyruvate  dehydrogenase,  thereby  limiting  carbon  flux  through  glycolysis.  Synthesis  of
glycogen is also affected in P P A R ? − /−  mice, which may be mediated in part via defective regulation of
Gys2 [152]. It is noteworthy that in contrast to studies in mice, human trials generally do not support
an effect of P P A R ?  activation on plasma glucose levels. Consistent with these data, it was found that
upregulation of genes involved in the glycolysis/gluconeogenesis pathway by Wy14643 was uniquely
observed in mouse hepatocytes and not human hepatocytes [24].
8. PPAR? and Hepatic Cholesterol/Bile Metabolism
It has been demonstrated that P P AR?  activation increases efflux of cholesterol to HDL. Formation of
nascent HDL is mediated by Abca1-dependent lipidation of newly-secreted Apoa1. Expression of Abca1
is upregulated by P P A R ? agonists in both human and mouse hepatocytes, as well as in mouse intestine
[24, 237]. Presently, it is not clear if this effect of P PAR?  activation is mediated via LXR?,  as was
shown previously in macrophages [21]. Other genes involved in cholesterol uptake and transport that
were shown to be under control of PPA R ? include Abcg5, Abcg8, Cav1, Npc1, and Rab9 [24, 62, 144].
While P P A R ?  is known to govern specific genes involved in bile acid synthesis, the overall impact on
bile  acid  homeostasis  remains  somewhat  ambiguous.  Expression  of  Cyp7a1,  which  represents  the
rate-limiting enzyme in  bile acid synthesis, is markedly downregulated in  PPAR?− /−  mice in  fasting
condition [62]. Paradoxically, synthetic P P A R ?  agonists reduce Cyp7a1 expression in both mice and
human [145, 238–240]. In agreement with the latter observation, fibrate treatment leads to decreased
bile  acid  synthesis.  To  what  extent  the  changes in  Cyp7a1  expression  reflect  direct  regulation  by
P P A R ? is unclear as P P A R ? also influences the expression of other nuclear hormone receptors involved
in regulation of Cyp7a1 such as FXR and LXR. It has also been suggested that PPAR?  can antagonize
LXR signaling and LXR-dependent activation of Cyp7a1 gene promoter [241–243].
Other  genes involved in  bile acid synthesis that are regulated by PPAR?  include Cyp27a1 which is
downregulated  by  P P A R ?  agonists  in  a  P P A R ? -dependent  manner  [145],  and  Cyp8b1  which  is
upregulated by P P A R ?  [62, 148]. Recently, CYP7b1 expression was shown to be suppressed by PPAR?
in a sex-specific manner, which was shown to occur via sumoylation of the LBD of PPAR? [244]. Finally,
P P A R ? stimulates expression of the hepatobiliary phospholipid transporter Abcb4 [24, 62, 94, 144].
9. PPAR? and Amino Acid Metabolism
Accumulating evidence supports a role for  P P A R ?  in  regulation of amino acid and urea metabolism
[159, 160, 162, 245]. Studies in mice have shown that PPAR?  governs metabolism of amino acids by
suppressing  expression  of  genes  involved  in  transamination  (Aspartate  amino  transferase  (Got1),
Alanine  amino  transferase  (Gpt),  Alanine  glyoxylate  aminotransferase  (Agtx2),  and  deamination
(Glutaminase (Gls)), as well as numerous genes that are part of the urea cycle (Cps1, Otc, Ass1, and
Asl) [160, 161, 245]. In  agreement with these data, PPAR?− /−  mice exhibit increased plasma urea
levels [160]. Several of the above genes were also downregulated by PPAR?  agonist in primary human
hepatocytes,  suggesting  that  regulation  of  nitrogen  metabolism  by  PPAR?  is  at  least  partially
conserved between mice and human [24].
At the present time, the mechanism behind downregulation of nitrogen metabolism by PPAR?  remains
elusive. It has been proposed that PPA R ?  may modulate the activity of other transcription factors that
are  directly  involved  in  amino  acid  homeostasis,  including  HNF4?  and  C/EBP?  [160].  However,
concrete evidence supporting such a mechanism is lacking.
Whereas P P A R ?  activation  decreases hepatic aminotransferase expression  in  mice, PPAR?  agonists
were shown to increase expression of Gpt in human hepatocytes and HepG2 cells, which occurred via
direct regulation of the gene promoter  [161, 246]. The observed increase in  plasma alanine amino
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transferase activity in patients treated with fibrates may thus be related to direct regulation of Gpt
transcription, rather than drug-induced liver injury.
10. PPAR? and Inflammation
Besides regulating numerous metabolic pathways, P P A R?  also governs inflammatory processes, which
is  mainly  achieved  by  downregulating  gene  expression  via  a  mechanism generally  referred  to  as
transrepression. The first clue towards anti-inflammatory effects of PPAR?  came from the observation
that  P P A R ? − / −  mice  exhibit  a  prolonged inflammatory  response  in  the  ear  swelling test  [53].  The
anti-inflammatory effects of P P A R ?  are likely explained by interference of PPAR?  with the activity of
many proinflammatory transcription factors including signal transducer and activator of transcription
(Stat), Activator  protein-1  (AP-1), and NF-? B [247]. Specifically, it  has been  shown that  activated
P P A R ?  binds to c-Jun and to the p65 subunit of NF-? B, thereby inhibiting AP-1- and NF-?B- mediated
signaling [248]. Additionally, P P A R ?  induces the inhibitory protein I?B?, which normally retains NF-?B
in  a  nonactive  form,  leading  to  suppression  of  NF-? B  DNA-binding  activity  [168].  Suppression  of
fibrinogen  gene  expression  by  PPA R ?  activation  is  likely  mediated  by  interference  with  the
transcription  factor  CAATT/enhancer-binding  protein  (C/EBP)  via  sequestration  of  the  coactivator
glucocorticoid receptor-interacting protein 1/transcriptional intermediary factor 2 (GRIP1/TIF2) [166].
Finally, recent data indicate that activated P P A R ?  may downregulate gene expression by causing the
loss of STAT1 and STAT3 binding to DNA [12].
Specific genes downregulated by P PAR ?  include a number of acute phase genes such as fibrinogen,
serum amyloid P-component, lipocalin 2, metallothioneins, and serum amyloid A2, which were shown
to be suppressed by the P P A R ?  agonist  Wy14643 in  wild-type mice but not PPAR?− /−  mice [163].
Similarly, in humans fenofibrate treatment has been shown to decrease plasma levels of several acute
phase proteins including C-reactive protein, fibrinogen-? and -? and interleukin 6 [166, 249, 250].
With the exception of the sIl-1 receptor antagonist and Vanin-1, to our knowledge no inflammatory
genes have been identified as direct positive targets of PPAR? [163].
The  Vanin-1  (Vnn1)  gene  encodes  a  glycosylphosphati-dylinositol-linked  membrane-associated
pantetheinase  that  generates cysteamine  from pantothenic  acid.  Studies  suggest  that  Vanin1  may
promote inflammation. Mice lacking Vnn1 showed decreased NSAID- or Schistosoma-induced intestinal
inflammation, which was associated with higher glutathione levels [251]. Other evidence indicates that
Vanin-1  stimulates production  of  inflammatory  mediators  by  intestinal  epithelial  cells  and thereby
controls  the  innate  immune  response,  possibly  by  antagonizing  PPAR?  activity  [252].  Epithelial
Vanin-1  was also found to  regulate  inflammation-driven  cancer  development  in  a  colitis-associated
colon cancer model [253]. Evidence presented in Figure 3 demonstrates that Vnn1 likely represents a
direct target gene of P P A R ? . Expression of Vnn1 in mouse liver was markedly increased by fasting in
wildtype but not P P A R ? − / −  mice (Figure 3(a)). Negligible Vnn1 expression was detected in PPAR?− /−
mouse liver. Moreover, hepatic Vnn1 expression was significantly induced by 6 h treatment with dietary
fatty acids and by the synthetic PPARα agonists Wy14643 and fenofibrate (Figure 3(b)). Additional data
lend strong support to the importance of P P A R ?  in Vnn1 gene regulation in small and large intestine
(Figures 3(c) and 3(d)), although the results are not quite as striking as in liver. Finally, it was shown
that two adjacent and partially overlapping PPREs located around 4 kb downstream of the transcription
start site of the mouse Vnn1 gene were functional in a luciferase reporter assay in HepG2 cells (Figure
3(e)). P P A R ?  transfection and Wy14643 markedly increased luciferase activity, although for reasons
that  remain  unclear,  no synergism between  the  two treatments was observed. Overall,  these  data
suggest that Vnn1 represents a direct P P A R ? target gene.
Figure  3:  Vanin-1  likely  represents  a  direct  ?????  target  gene.  (a)  Vnn1
expression in livers of ad libitum fed and 24 h fasted wildtype and PPAR?− /−  mice.
(b) Vnn1 expression in liver, (c) small intestine, and (d) large intestine of wildtype
and P P A R ? − / −  mice 6 h after administration of a single oral dose of Wy14643 (4 
mg), fenofibrate (4 mg), and synthetic triglycerides triolein, trilinolein, trilinolenin,
trieicosapentaenoin,  or  tridocosahexaenoin  (400 mL).  (e)  HepG2  cells  were
transiently  transfected with  reporters (PPRE)3-TK-LUC or  PPRE-Vnn1-LUC (PPRE
present in intron 3-4 of the Vnn1 gene cloned into pGL3-promoter) and PPAR?
expression plasmid (pSG5). After  transfection, cells were treated with WY14643
(50 ? M) for 24 hours followed by determination of luciferase and ?-galactosidase
activities  in  the  cell  lysates.  Luciferase  activities  were  normalized  to  ?
-galactosidase, and the relative luciferase activity of the cells treated with DMSO
was set to 1. Error bars represent SEM.
The ability of P P A R ? to stimulate fatty acid oxidation and suppress hepatic inflammation has led to the
exploration of P P A R ? agonists as a therapeutic option for nonalcohol fatty liver disease and specifically
nonalcoholic steatohepatitis (NASH). Several  studies in mice have shown that PPAR?  activation can
reduce or  even  reverse  the progression  of  steatohepatitis [193, 254–259]. The inhibitory  effect  of
P P A R ?  on  progression  of steatosis to steatohepatitis may be mediated in  part  by  COX2 (Ptgs2), a
candidate gene involved in  steatohepatitis development that is suppressed by PPAR?  [260]. In  the
absence of P P A R ? ,  liver steatosis and inflammation are enhanced in mice chronically fed a HFD [165].
Whether the effects of P P A R ? on NASH are primarily related to changes in hepatic TG content or occur
via direct suppression of inflammatory genes and markers remains unclear.
11. PPAR? and Biotransformation
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The  detoxification  of  endogenous and exogenous molecules  is  generally  divided into  three  distinct
biotransformation  phases. The phase I reaction  involves the introduction  of  a  polar  group into the
xenobiotic molecule and is catalyzed by members of the cytochrome P450 (CYP) superfamily [179, 180,
261]. Phase II enzymes are responsible for covalent linkage of the absorbed chemicals or products of
the phase I reactions with compounds such as glutathione, glucuronic acid, or  amino acids and are
carried  out  by  sulfotransferases,  UDP-glucuronosyltransferases  (UGTs),  glutathione-  S-transferases
(GSTs), and N-acetyltransferases [261]. The third phase corresponds to elimination of the conjugated
molecule from cells and their excretion into bile or urine via specific transporters, mainly members of
the  superfamily  ATP-binding  cassette  transporter  proteins  [262,  263].  Studies  have  shown  that
peroxisome proliferators modulate  exclusively  the Cyp4a class of  monooxygenases (involved in  the
metabolism of biologically important compounds such as fatty acids, see Section 5.3) in mouse while
regulating various other Cyp genes in human hepatocytes, including members of the Cyp1a, Cyp2a,
Cyp2c,  and  Cyp2e  subfamilies  [24].  Our  recent  microarray  data  confirmed  the  human  specific
regulation  of  Cyp  genes  belonging  to  classes  1-3  by  PPAR?  in  primary  human  hepatocytes.
Interestingly, we also observed a significant induction of another subfamily member of Cyp4 enzymes,
Cyp4x1, by P P A R ? in human primary hepatocytes which was not conserved in mouse [24]. Cyp4x1 has
been shown to be involved in oxidation of anandamide, which represents one of the endocannabinoids.
Besides upregulation of gene expression, a number of genes involved in phase I biotransformation are
downregulated by P P A R ? in mice, including Cyp2a5, Cyp2c11, Cup2c12, and Cyp2c29 [110, 155].
With  respect  to  phase  II  biotransformation,  P P A R ?  has been  shown  to downregulate  Glutathione-
S-transferase A [GSTA], possibly leading to decreased biliary excretion of glutathione conjugates [157,
264, 265]. In contrast, expression of UDP-glucuronosyltransferase 1A (Ugt1a9), which participates with
other UGT enzymes in glucuronidation of bilirubin, arachidonic, and linoleic acid metabolites, is under
direct stimulatory control of P P A R ?  [158]. Overall, it is evident that PPAR?  is a major regulator of
biotransformation  enzymes  and  governs  the  expression  of  numerous  cytochrome  P-450  and
conjugating enzymes. However, only a small portion of the regulation seems to be conserved between
rodents and humans.
12. Conclusion
In 2010, we are celebrating the 20th anniversary of the discovery of PPAR?  by Isseman and Green.
P P A R ?  was initially isolated as a novel nuclear hormone receptor that serves as molecular target of a
diverse class of rodent hepatocarcinogens. Since then it has become clear that PPAR?  can be activated
by a large variety of endogenous and synthetic agonists including fibrate  drugs. In  fact, PPAR?  is
nowadays considered as a crucial fatty acids sensor that mediates the effects of numerous fatty acids
and fatty acid derivatives on gene expression. Furthermore, over the years PPAR?  has emerged as a
crucial transcriptional regulator of numerous metabolic and inflammatory processes. Although PPAR?
has mostly been connected with stimulation of fatty acid oxidation, it is now evident that the effects of
P P A R ?  are much more widespread and cover  numerous aspects of nutrient metabolism and energy
homeostasis,  including  metabolism  of  lipoproteins,  glucose/glycerol,  cholesterol  and  bile  acids,
xenobiotics,  and  amino  acids.  Certainly,  P P A R ?  merits  the  classification  as  a  master  regulator  of
hepatic  intermediary  metabolism. Until  recently,  much  confusion  surrounded the  effects  of  PPAR?
activation in human liver. Recent studies indicate that at least in terms of lipid metabolism, the function
and specific target genes of P P A R ?  are generally well conserved between mouse and human. One of
the  major  challenges  lying  ahead  is  to  gain  better  understanding  of  the  molecular  mechanism
underlying  downregulation  of  gene  expression  by  PPAR?,  to  improve  insight  into  the  specific
mechanisms  and  pathways  of  endogenous  P P A R ?  activation,  and  to  better  link  the  functional
consequences of P P A R ? activation to induction of specific PPAR? target genes.
Acknowledgment
B. Knoch was funded by AgResearch within the Nutrigenomics New Zealand partnership.
References
B.  Desvergne  and W.  Wahli,  “Peroxisome  proliferator-activated  receptors:  nuclear  control  of
metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
1.
S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in health and disease,” Nature, vol.
405, no. 6785, pp. 421–424, 2000.
2.
R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature
Medicine, vol. 10, no. 4, pp. 355–361, 2004.
3.
A.  IJpenberg,  E.  Jeannin,  W.  Wahli,  and  B.  Desvergne,  “Polarity  and  specific  sequence
requirements  of  peroxisome  proliferator-activated  receptor  (PPAR)/retinoid  X  receptor
heterodimer  binding to DNA. A  functional  analysis of  the malic enzyme gene PPAR response
element,” Journal of Biological Chemistry, vol. 272, no. 32, pp. 20108–20117, 1997.
4.
O.  Braissant,  F.  Foufelle,  C.  Scotto,  M.  Dauça,  and  W.  Wahli,  “Differential  expression  of
peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in
the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
5.
P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W. Wahli, and B. Desvergne, “Rat PPARs:
quantitative analysis in adult rat tissues and regulation in fasting and refeeding,” Endocrinology,
vol. 142, no. 10, pp. 4195–4202, 2001.
6.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
8 van 21 19-8-2011 11:55
H.  E.  Xu,  T.  B.  Stanley,  V.  G.  Montana  et  al.,  “Structural  basis  for  antagonist-mediated
recruitment of nuclear co-repressors by PPARα,” Nature, vol. 415, no. 6873, pp. 813–817, 2002.
7.
I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily
by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
8.
J. M. Thorp and W. S. Waring, “Modification of metabolism and distribution of lipids by ethyl
chlorophenoxyisobutyrate,” Nature, vol. 194, no. 4832, pp. 948–949, 1962.
9.
T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors
to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000.
10.
J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol.
53, pp. 409–435, 2002.
11.
D. L. M. van der Meer, T. Degenhardt, S. Väisänen et al., “Profiling of promoter occupancy by
PPARα in human hepatoma cells via ChIP-chip analysis,” Nucleic Acids Research, vol. 38, no. 9,
pp. 2839–2850, 2010.
12.
M. I. Lefterova, Y. Zhang, D. J. Steger et al., “PPARγ and C/EBP factors orchestrate adipocyte
biology via adjacent binding on a genome-wide scale,” Genes and Development, vol. 22, no. 21,
pp. 2941–2952, 2008.
13.
R. Nielsen, T. Å. Pedersen, D. Hagenbeek et al., “Genome-wide profiling of PPARγ:RXR and RNA
polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes
in RXR dimer composition during adipogenesis,” Genes and Development, vol. 22, no. 21, pp.
2953–2967, 2008.
14.
M. Hoekstra, J.  K. Kruijt,  M. Van  Eck, and T. J.  C. Van  Berkel,  “Specific gene expression  of
ATP-binding  cassette  transporters  and  nuclear  hormone  receptors  in  rat  liver  parenchymal,
endothelial,  and  Kupffer  cells,”  Journal  of  Biological  Chemistry,  vol.  278,  no.  28,  pp.
25448–25453, 2003.
15.
J. M. Peters, I. Rusyn, M. L. Rose, F. J. Gonzalez, and R. G. Thurman, “Peroxisome proliferator-
activated receptor α is restricted to hepatic parenchymal cells, not Kupffer cells: implications for
the mechanism of action of peroxisome proliferators in hepatocarcinogenesis,” Carcinogenesis,
vol. 21, no. 4, pp. 823–826, 2000.
16.
A. L. Bookout, Y. Jeong, M. Downes, R. T. Yu, R. M. Evans, and D. J. Mangelsdorf, “Anatomical
profiling of nuclear receptor expression reveals a hierarchical transcriptional network,” Cell, vol.
126, no. 4, pp. 789–799, 2006.
17.
N. Marx, B. Kehrle, K. Kohlhammer et al., “PPAR activators as antiinflammatory mediators in
human  T  lymphocytes:  implications  for  atherosclerosis  and  transplantation-associated
arteriosclerosis,” Circulation Research, vol. 90, no. 6, pp. 703–710, 2002.
18.
G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ
induces apoptosis of  human  monocyte-derived macrophages,” Journal of  Biological Chemistry,
vol. 273, no. 40, pp. 25573–25580, 1998.
19.
N. Marx, N. Mackman, U. Schönbeck et al., “PPARα activators inhibit tissue factor expression and
activity in human monocytes,” Circulation, vol. 103, no. 2, pp. 213–219, 2001.
20.
G.  Chinetti,  S.  Lestavel,  V.  Bocher  et  al.,  “PPAR-α  and PPAR-γ  activators  induce  cholesterol
removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature
Medicine, vol. 7, no. 1, pp. 53–58, 2001.
21.
F. G. Gbaguidi, G. Chinetti, D. Milosavljevic et al., “Peroxisome proliferator-activated receptor
(PPAR)  agonists  decrease  lipoprotein  lipase  secretion  and  glycated  LDL  uptake  by  human
macrophages,” FEBS Letters, vol. 512, no. 1–3, pp. 85–90, 2002.
22.
C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, J. L. Raucy, and E. F. Johnson, “Peroxisome proliferator
activated receptor-α  expression  in  human liver,”  Molecular  Pharmacology,  vol.  53, no. 1, pp.
14–22, 1998.
23.
M.  Rakhshandehroo,  G.  Hooiveld,  M.  Müller,  and S.  Kersten,  “Comparative  analysis  of  gene
regulation by the transcription factor PPARα between mouse and human,” PLoS ONE, vol. 4, no.
8, Article ID e6796, 2009.
24.
R. Hi, S. Osada, N. Yumoto, and T. Osumi, “Characterization of the amino-terminal  activation
domain of peroxisome proliferator-activated receptor α. Importance of α-helical structure in the
transactivating function,” Journal of Biological Chemistry, vol. 274, no. 49, pp. 35152–35158,
1999.
25.
P. Cronet, J. F. W. Petersen, R. Folmer  et al., “Structure of the PPARα and -γ  ligand binding
domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family,”
Structure, vol. 9, no. 8, pp. 699–706, 2001.
26.
C.  Diradourian,  J.  Girard,  and  J.-P.  Pégorier,  “Phosphorylation  of  PPARs:  from  molecular
characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005.
27.
Y.-J.  Y.  Wan,  Y.  Cai,  W.  Lungo  et  al.,  “Peroxisome  proliferator-activated receptor  α-mediated
pathways  are  altered in  hepatocyte-specific  retinoid  x  receptor  α-deficient  mice,”  Journal  of
28.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
9 van 21 19-8-2011 11:55
Biological Chemistry, vol. 275, no. 36, pp. 28285–28290, 2000.
H.  E.  Xu,  M.  H.  Lambert,  V.  G.  Montana  et  al.,  “Structural  determinants  of  ligand  binding
selectivity between the peroxisome proliferator-activated receptors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13919–13924, 2001.
29.
H. E. Xu, M. H. Lambert, V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome
proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999.
30.
A. Sapone, J. M. Peters, S. Sakai et al., “The human peroxisome proliferator-activated receptor α
gene:  identification  and  functional  characterization  of  two  natural  allelic  variants,”
Pharmacogenetics, vol. 10, no. 4, pp. 321–333, 2000.
31.
D. M. Flavell, I. Pineda Torra, Y. Jamshidi et al., “Variation in the PPARα gene is associated with
altered  function  in  vitro  and  plasma  lipid  concentrations  in  type  II  diabetic  subjects,”
Diabetologia, vol. 43, no. 5, pp. 673–680, 2000.
32.
C. Lacquemant, F. Lepretre, I. Pineda Torra et al., “Mutation screening of the PPARα gene in type
2 diabetes associated with coronary heart disease,” Diabetes and Metabolism, vol. 26, no. 5, pp.
393–401, 2000.
33.
M.-C.  Vohl,  P.  Lepage,  D.  Gaudet  et  al.,  “Molecular  scanning  of  the  human  PPARα  gene:
association of the L162V mutation with hyperapobetalipoproteinemia,” Journal of Lipid Research,
vol. 41, no. 6, pp. 945–952, 2000.
34.
D. Evans, J. Aberle, D. Wendt, A. Wolf, U. Beisiegel, and W. A. Mann, “A polymorphism, L162V, in
the  peroxisome proliferator-activated receptor  α  (PPARα)  gene  is associated with  lower  body
mass  index  in  patients  with  non-insulin-dependent  diabetes  mellitus,”  Journal  of  Molecular
Medicine, vol. 79, no. 4, pp. 198–204, 2001.
35.
I.  Gouni-Berthold, E. Giannakidou, D. Müller-Wieland et  al.,  “Association  between  the PPARα
L162V  polymorphism,  plasma  lipoprotein  levels,  and atherosclerotic  disease  in  patients  with
diabetes mellitus type 2 and in nondiabetic controls,” American Heart Journal, vol. 147, no. 6,
pp. 1117–1124, 2004.
36.
D. M. Flavell, Y. Jamshidi, E. Hawe et  al., “Peroxisome proliferator-activated receptor  α  gene
variants influence progression of coronary atherosclerosis and risk of coronary artery disease,”
Circulation, vol. 105, no. 12, pp. 1440–1445, 2002.
37.
E.  S.  Tai,  D.  Corella,  S.  Demissie  et  al.,  “Polyunsaturated  fatty  acids  interact  with  the
PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations
in the Framingham Heart Study,” Journal of Nutrition, vol. 135, no. 3, pp. 397–403, 2005.
38.
D.  Brisson,  K.  Ledoux,  Y.  Bosse  et  al.,  “Effect  of  apolipoprotein  E,  peroxisome proliferator-
activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to
improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients,”
Pharmacogenetics, vol. 12, no. 4, pp. 313–320, 2002.
39.
Y. Bossé, A. Pascot, M. Dumont et al., “Influences of the PPARα-L162V polymorphism on plasma
HDL 2-cholesterol  response  of  abdominally  obese  men  treated with  gemfibrozil,”  Genetics in
Medicine, vol. 4, no. 4, pp. 311–315, 2002.
40.
K. Yamakawa-Kobayashi, H. Ishiguro, T. Arinami, R. Miyazaki, and H. Hamaguchi, “A Val227Ala
polymorphism  in  the  peroxisome  proliferator  activated  receptor  alpha  (PPARalpha)  gene  is
associated with variations in serum lipid levels,” Journal of Medical Genetics, vol. 39, no. 3, pp.
189–191, 2002.
41.
H. Naito, O. Yamanoshita, M. Kamijima et al., “Association of V227A PPARα polymorphism with
altered  serum  biochemistry  and  alcohol  drinking  in  Japanese  men,”  Pharmacogenetics  and
Genomics, vol. 16, no. 8, pp. 569–577, 2006.
42.
H. Naito, M. Kamijima, O. Yamanoshita et al., “Differential effects of aging, drinking and exercise
on  serum  cholesterol  levels  dependent  on  the  PPARA-V227A  polymorphism,”  Journal  of
Occupational Health, vol. 49, no. 5, pp. 353–362, 2007.
43.
S. Chen, Y. Li, S. Li, and C. Yu, “A Val227Ala substitution in the peroxisome proliferator activated
receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased
waist circumference and waist-to-hip ratio,” Journal of Gastroenterology and Hepatology, vol. 23,
no. 9, pp. 1415–1418, 2008.
44.
P.  Gervois,  I.  Pineda  Torra,  G.  Chinetti  et  al.,  “A  truncated human  peroxisome  proliferator-
activated receptor α splice variant with dominant negative activity,” Molecular Endocrinology, vol.
13, no. 9, pp. 1535–1549, 1999.
45.
J. C. Fruchart, P. Duriez, and B. Staels, “Molecular mechanism of action of the fibrates,” Journal
de la Societe de Biologie, vol. 193, no. 1, pp. 67–75, 1999.
46.
K. Schoonjans, B. Staels, and J. Auwerx, “Role of the peroxisome proliferator-activated receptor
(PPAR) in mediating the effects of fibrates and fatty acids on gene expression,” Journal of Lipid
Research, vol. 37, no. 5, pp. 907–925, 1996.
47.
S.  A.  Khan  and  J.  P.  Vanden  Heuvel,  “Role  of  nuclear  receptors  in  the  regulation  of  gene
expression by dietary fatty acids (review),” Journal of Nutritional Biochemistry, vol. 14, no. 10,
48.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
10 van 21 19-8-2011 11:55
pp. 554–567, 2003.
S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty  acids and eicosanoids regulate gene
expression through direct interactions with peroxisome proliferator-activated receptors α and γ,”
Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9,
pp. 4318–4323, 1997.
49.
B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and
eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of
the  National  Academy  of  Sciences  of  the  United  States  of  America,  vol.  94,  no.  9,  pp.
4312–4317, 1997.
50.
H. Keller, C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli, “Fatty acids and retinoids
control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid
X receptor heterodimers,” Proceedings of the National Academy of Sciences of the United States
of America, vol. 90, no. 6, pp. 2160–2164, 1993.
51.
K. Yu, W. Bayona, C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated
receptors by eicosanoids,” Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983,
1995.
52.
P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPARα-
leukotriene B4 pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996.
53.
S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, “Peroxisome
proliferator-activated receptor α mediates the adaptive response to fasting,” Journal of Clinical
Investigation, vol. 103, no. 11, pp. 1489–1498, 1999.
54.
T. C. Leone, C. J. Weinheimer, and D. P. Kelly, “A critical role for the peroxisome proliferator-
activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model
of fatty acid oxidation disorders,” Proceedings of the National Academy of Sciences of the United
States of America, vol. 96, no. 13, pp. 7473–7478, 1999.
55.
L. M. Sanderson, T. Degenhardt, A. Koppen et al., “Peroxisome proliferator-activated receptor β/δ
(PPARβ/δ)  but  not  PPARα  serves as a  plasma  free  fatty  acid sensor  in  liver,”  Molecular  and
Cellular Biology, vol. 29, no. 23, pp. 6257–6267, 2009.
56.
M. V. Chakravarthy, Z. Pan, Y. Zhu et al., ““New” hepatic fat activates PPARα to maintain glucose,
lipid, and cholesterol homeostasis,” Cell Metabolism, vol. 1, no. 5, pp. 309–322, 2005.
57.
D. Patsouris, J. K. Reddy, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α
mediates the effects of high-fat diet on hepatic gene expression,” Endocrinology, vol. 147, no. 3,
pp. 1508–1516, 2006.
58.
P. G. P. Martin, H. Guillou, F. Lasserre et al., “Novel aspects of PPARα-mediated regulation of lipid
and xenobiotic metabolism revealed through a nutrigenomic study,” Hepatology, vol. 45, no. 3,
pp. 767–777, 2007.
59.
B. Ren, A. P. Thelen, J. M. Peters, F. J. Gonzalez, and D. B. Jump, “Polyunsaturated fatty acid
suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome
proliferator-activated  receptor  α,”  Journal  of  Biological  Chemistry,  vol.  272,  no.  43,  pp.
26827–26832, 1997.
60.
L.  M.  Sanderson,  P.  J.  de  Groot,  G.  J.  E.  J.  Hooiveld  et  al.,  “Effect  of  synthetic  dietary
triglycerides: a novel research paradigm for nutrigenomics,” PLoS ONE, vol. 3, no. 2, Article ID
e1681, 2008.
61.
M. Rakhshandehroo, L. M. Sanderson, M. Matilainen et al., “Comprehensive analysis of PPARα-
dependent regulation of hepatic lipid metabolism by expression profiling,” PPAR Research, vol.
2007, Article ID 26839, 13 pages, 2007.
62.
L. Guo, H. Fang, J. Collins et al., “Differential  gene expression in mouse primary hepatocytes
exposed to the peroxisome proliferator-activated receptor α agonists,” BMC Bioinformatics, vol. 7,
supplement 2, p. S18, 2006.
63.
K. Motojima, P. Passilly, J. M. Peters, F. J. Gonzalez, and N. Latruffe, “Expression of putative fatty
acid  transporter  genes  are  regulated  by  peroxisome  proliferator-activated  receptor  α  and  γ
activators in a tissue- and inducer-specific manner,” Journal of Biological Chemistry, vol. 273, no.
27, pp. 16710–16714, 1998.
64.
K. Yamazaki, J. Kuromitsu, and I. Tanaka, “Microarray analysis of gene expression changes in
mouse liver induced by peroxisome proliferator-activated receptor α agonists,” Biochemical and
Biophysical Research Communications, vol. 290, no. 3, pp. 1114–1122, 2002.
65.
G. Martin, K. Schoonjans, A.-M. Lefebvre, B. Staels, and J. Auwerx, “Coordinate regulation of the
expression  of  the  fatty  acid transport  protein  and acyl-CoA  synthetase  genes by  PPARα  and
PPARγ activators,” Journal of Biological Chemistry, vol. 272, no. 45, pp. 28210–28217, 1997.
66.
B.  I.  Frohnert,  T.  Y.  Hui,  and  D.  A.  Bernlohr,  “Identification  of  a  functional  peroxisome
proliferator-responsive  element  in  the  murine  fatty  acid  transport  protein  gene,”  Journal  of
Biological Chemistry, vol. 274, no. 7, pp. 3970–3977, 1999.
67.
L. Richert, C. Lamboley, C. Viollon-Abadie et al., “Effects of clofibric acid on mRNA expression68.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
11 van 21 19-8-2011 11:55
profiles  in  primary  cultures  of  rat,  mouse  and  human  hepatocytes,”  Toxicology  and  Applied
Pharmacology, vol. 191, no. 2, pp. 130–146, 2003.
M. C. Hunt, P. J. G. Lindquist, J. M. Peters, F. J. Gonzalez, U. Diczfalusy, and S. E. H. Alexson,
“Involvement  of  the  peroxisome  proliferator-activated  receptor  α  in  regulating  long-chain
acyl-CoA thioesterases,” Journal of Lipid Research, vol. 41, no. 5, pp. 814–823, 2000.
69.
T.  Aoyama,  J.  M.  Peters,  N.  Iritani  et  al.,  “Altered  constitutive  expression  of  fatty
acid-metabolizing  enzymes  in  mice  lacking  the  peroxisome  proliferator-activated  receptor  α
(PPARα),” Journal of Biological Chemistry, vol. 273, no. 10, pp. 5678–5684, 1998.
70.
M.-H. Hsu, Ü. Savas, K. J. Griffin, and E. F. Johnson, “Identification of peroxisome proliferator-
responsive  human  genes  by  elevated  expression  of  the  peroxisome  proliferator-activated
receptor  alpha  in  HepG2  cells,”  Journal  of  Biological  Chemistry,  vol.  276,  no.  30,  pp.
27950–27958, 2001.
71.
K. Schoonjans, M. Watanabe, H. Suzuki  et al., “Induction of the acyl-coenzyme A synthetase
gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in
the C promoter,” Journal of Biological Chemistry, vol. 270, no. 33, pp. 19269–19276, 1995.
72.
T. M. Lewin, C. G. Van Horn, S. K. Krisans, and R. A. Coleman, “Rat liver acyl-CoA synthetase 4
is a  peripheral-membrane protein  located in  two distinct  subcellular  organelles, peroxisomes,
and mitochondrial-associated membrane,” Archives of Biochemistry and Biophysics, vol. 404, no.
2, pp. 263–270, 2002.
73.
T. Hashimoto, T. Fujita, N. Usuda et al., “Peroxisomal and mitochondrial fatty acid β-oxidation in
mice  nullizygous  for  both  peroxisome  proliferator-activated  receptor  and  peroxisomal  fatty
acyl-CoA  oxidase:  genotype  correlation  with  fatty  liver  phenotype,”  Journal  of  Biological
Chemistry, vol. 274, no. 27, pp. 19228–19236, 1999.
74.
H.  Poirier,  I.  Niot,  M.-C.  Monnot  et  al.,  “Differential  involvement of peroxisome-proliferator-
activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding
liver  fatty-acid-binding protein  in  the liver  and the small  intestine,” Biochemical Journal, vol.
355, no. 2, pp. 481–488, 2001.
75.
J. P. Vanden Heuvel, D. Kreder, B. Belda et al., “Comprehensive analysis of gene expression in
rat and human hepatoma cells exposed to the peroxisome proliferator  WY14,643,” Toxicology
and Applied Pharmacology, vol. 188, no. 3, pp. 185–198, 2003.
76.
J. M. Brandt, F. Djouadi, and D. P. Kelly, “Fatty acids activate transcription of the muscle carnitine
palmitoyltransferase  I  gene  in  cardiac  myocytes  via  the  peroxisome  proliferator-activated
receptor α,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 23786–23792, 1998.
77.
C. Mascaró, E. Acosta, J. A. Ortiz, P. F. Marrero, F. G. Hegardt, and D. Haro, “Control of human
muscle-type  carnitine  palmitoyltransferase  I  gene  transcription  by  peroxisome  proliferator-
activated receptor,” Journal of Biological Chemistry, vol. 273, no. 15, pp. 8560–8563, 1998.
78.
L.  Napal,  P.  F.  Marrero, and D. Haro,  “An intronic peroxisome proliferator-activated receptor-
binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A,”
Journal of Molecular Biology, vol. 354, no. 4, pp. 751–759, 2005.
79.
M.  J.  Barrero,  N.  Camarero,  P.  F.  Marrero,  and  D.  Haro,  “Control  of  human  carnitine
palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through
a partially conserved peroxisome proliferator-responsive element,” Biochemical Journal, vol. 369,
no. 3, pp. 721–729, 2003.
80.
E.  H.  Hakkola,  J.  K.  Hiltunen,  and  H.  I.  Autio-Harmainen,  “Mitochondrial  2,4-dienoyl-CoA
reductases in the rat: differential responses to clofibrate treatment,” Journal of Lipid Research,
vol. 35, no. 10, pp. 1820–1828, 1994.
81.
K. Tachibana, Y. Kobayashi, T. Tanaka et al., “Gene expression profiling of potential peroxisome
proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly
expressing PPAR isoforms,” Nuclear Receptor, vol. 3, Article ID 3, 2005.
82.
B. Zhang, S. L. Marcus, F. G. Saijadi et al., “Identification of a peroxisome proliferator-responsive
element  upstream  of  the  gene  encoding  rat  peroxisomal  enoyl-CoA  hydratase/3-
hydroxyacyl-CoA dehydrogenase,” Proceedings of the National Academy of Sciences of the United
States of America, vol. 89, no. 16, pp. 7541–7545, 1992.
83.
A.  Gutgesell,  G.  Wen,  B.  König  et  al.,  “Mouse  carnitine-acylcarnitine  translocase  (CACT)  is
transcriptionally regulated by PPARα and PPARδ in liver cells,” Biochimica et Biophysica Acta, vol.
1790, no. 10, pp. 1206–1216, 2009.
84.
N.  van  Vlies,  S.  Ferdinandusse,  M.  Turkenburg,  R.  J.  A.  Wanders,  and  F.  M.  Vaz,  “PPARα-
activation  results  in  enhanced  carnitine  biosynthesis  and  OCTN2-mediated  hepatic  carnitine
accumulation,” Biochimica et Biophysica Acta, vol. 1767, no. 9, pp. 1134–1142, 2007.
85.
S. Luci, S. Geissler, B. König et al., “PPARα agonists up-regulate organic cation transporters in
rat  liver  cells,”  Biochemical  and  Biophysical  Research  Communications,  vol.  350,  no.  3,  pp.
704–708, 2006.
86.
L. J. Kelly, P. P. Vicario, G. M. Thompson et al., “Peroxisome proliferator-activated receptors γ and87.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
12 van 21 19-8-2011 11:55
α  mediate  in  vivo regulation  of uncoupling protein  (UCP-1, UCP-2, UCP-3) gene expression,”
Endocrinology, vol. 139, no. 12, pp. 4920–4927, 1998.
M.  B.  Armstrong  and  H.  C.  Towle,  “Polyunsaturated  fatty  acids  stimulate  hepatic  UCP-2
expression via a PPARα-mediated pathway,” American Journal of Physiology, vol. 281, no. 6, pp.
E1197–E1204, 2001.
88.
N. Tsuboyama-Kasaoka, M. Takahashi, H. Kim, and O. Ezaki, “Up-regulation of liver uncoupling
protein-2  mRNA by either  fish  oil  feeding or  fibrate administration  in  mice,” Biochemical and
Biophysical Research Communications, vol. 257, no. 3, pp. 879–885, 1999.
89.
M. K. Badman, P. Pissios, A. R. Kennedy, G. Koukos, J. S. Flier, and E. Maratos-Flier, “Hepatic
fibroblast  growth  factor  21  is  regulated  by  PPARα  and  is  a  key  mediator  of  hepatic  lipid
metabolism in ketotic states,” Cell Metabolism, vol. 5, no. 6, pp. 426–437, 2007.
90.
T.  Lundåsen, M. C.  Hunt,  L.-M. Nilsson  et  al.,  “PPARα  is a  key  regulator  of  hepatic  FGF21,”
Biochemical and Biophysical Research Communications, vol. 360, no. 2, pp. 437–440, 2007.
91.
T.  Inagaki,  P.  Dutchak,  G.  Zhao  et  al.,  “Endocrine  regulation  of  the  fasting  response  by
PPARalpha-mediated induction of fibroblast growth factor 21,” Cell Metabolism, vol. 5, no. 6, pp.
415–425, 2007.
92.
C. Le May, T. Pineau, K. Bigot, C. Kohl, J. Girard, and J.-P. Pégorier, “Reduced hepatic fatty acid
oxidation in fasting PPARα null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA
synthase gene expression,” FEBS Letters, vol. 475, no. 3, pp. 163–166, 2000.
93.
T.  Kok,  V.  W.  Bloks,  H.  Wolters  et  al.,  “Peroxisome  proliferator-activated  receptor  α
(PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice,”
Biochemical Journal, vol. 369, no. 3, pp. 539–547, 2003.
94.
J. C. Rodríguez, G. Gil-Gómez, F. G. Hegardt, and D. Haro, “Peroxisome proliferator-activated
receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene
by fatty acids,” Journal of Biological Chemistry, vol. 269, no. 29, pp. 18767–18772, 1994.
95.
S. Fourcade, S. Savary, S. Albet et al., “Fibrate induction of the adrenoleukodystrophy-related
gene  (ABCD2):  promoter  analysis  and role  of  the  peroxisome proliferator-activated receptor
PPARα,” European Journal of Biochemistry, vol. 268, no. 12, pp. 3490–3500, 2001.
96.
M.  C.  Hunt,  K.  Solaas,  B.  F.  Kase,  and S.  E.  H.  Alexson,  “Characterization  of  an  acyl-CoA
thioesterase that  functions as a major  regulator  of  peroxisomal  lipid metabolism,” Journal of
Biological Chemistry, vol. 277, no. 2, pp. 1128–1138, 2002.
97.
C. Goldberg, “The pursuit of the fictional self,” American Journal of Psychotherapy, vol. 58, no. 2,
pp. 209–219, 2004.
98.
J. C. Corton, C. Bocos, E. S. Moreno, A. Merritt, R. C. Cattley, and J.-Å. Gustafsson, “Peroxisome
proliferators alter the expression of estrogen-metabolizing enzymes,” Biochimie, vol. 79, no. 2-3,
pp. 151–162, 1997.
99.
A. T. De Souza, X. Dai, A. G. Spencer  et al., “Transcriptional  and phenotypic comparisons of
Ppara  knockout  and  siRNA  knockdown  mice,”  Nucleic  Acids  Research,  vol.  34,  no.  16,  pp.
4486–4494, 2006.
100.
K.  Alvares,  C.  Fan,  S.  S.  Dadras  et  al.,  “An  upstream  region  of  the  enoyl-coenzyme  A
hydratase/3-hydroxyacyl- coenzyme A dehydrogenase gene directs luciferase expression in liver
in response to peroxisome proliferators in transgenic mice,” Cancer Research, vol. 54, no. 9, pp.
2303–2306, 1994.
101.
Y. Guo, R. A. Jolly, B. W. Halstead et al., “Underlying mechanisms of pharmacology and toxicity of
a novel PPAR agonist revealed using rodent and canine hepatocytes,” Toxicological Sciences, vol.
96, no. 2, pp. 294–309, 2007.
102.
J. C. Corton, C. Bocos, E. S. Moreno et al., “Rat 17β-hydroxysteroid dehydrogenase type IV is a
novel  peroxisome  proliferator-inducible  gene,”  Molecular  Pharmacology,  vol.  50,  no.  5,  pp.
1157–1166, 1996.
103.
L.-Q.  Fan,  R.  C.  Cattley,  and  J.  C.  Corton,  “Tissue-specific  induction  of  17β-hydroxysteroid
dehydrogenase type IV by peroxisome proliferator  chemicals is dependent on the peroxisome
proliferator-activated receptor α,” Journal of Endocrinology, vol. 158, no. 2, pp. 237–246, 1998.
104.
T. Wang, Y. M. Shah, T. Matsubara et al., “Control of steroid 21-oic acid synthesis by peroxisome
proliferator-activated receptor α and role of the hypothalamic-pituitary-adrenal axis,” Journal of
Biological Chemistry, vol. 285, no. 10, pp. 7670–7685, 2010.
105.
E. F. Johnson, C. N. A. Palmer, K. J. Griffin, and M.-H. Hsu, “Role of the peroxisome proliferator-
activated receptor in cytochrome P450 4A gene regulation,” FASEB Journal, vol. 10, no. 11, pp.
1241–1248, 1996.
106.
T. C. Aldridge, J. D. Tugwood, and S. Green, “Identification and characterization of DNA elements
implicated in the regulation of CYP4A1 transcription,” Biochemical Journal, vol. 306, no. 2, pp.
473–479, 1995.
107.
S. S.-T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the α isoform of the peroxisome108.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
13 van 21 19-8-2011 11:55
proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of
peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995.
D. L. Kroetz, P.  Yook, P.  Costet, P. Bianchi,  and T. Pineau, “Peroxisome proliferator-activated
receptor  controls the hepatic CYP4A induction  adaptive  response to starvation  and diabetes,”
Journal of Biological Chemistry, vol. 273, no. 47, pp. 31581–31589, 1998.
109.
T. B. Barclay, J. M. Peters, M. B. Sewer, L. Ferrari, F. J. Gonzalez, and E. T. Morgan, “Modulation
of  cytochrome P-450  gene expression  in  endotoxemic mice is tissue specific and peroxisome
proliferator-activated  receptor-α  dependent,”  Journal  of  Pharmacology  and  Experimental
Therapeutics, vol. 290, no. 3, pp. 1250–1257, 1999.
110.
S. P. Anderson, L. Yoon, E. B. Richard, C. S. Dunn, R. C. Cattley, and J. C. Corton, “Delayed liver
regeneration in peroxisome proliferator-activated receptor-α-null mice,” Hepatology, vol. 36, no.
3, pp. 544–554, 2002.
111.
B. L. Knight, A. Hebbach, D. Hauton et al., “A role for PPARα in the control of SREBP activity and
lipid synthesis in the liver,” Biochemical Journal, vol. 389, no. 2, pp. 413–421, 2005.
112.
Y.  Wang, D.  Botolin,  J.  Xu  et  al.,  “Regulation  of  hepatic  fatty  acid elongase  and desaturase
expression in diabetes and obesity,” Journal of Lipid Research, vol. 47, no. 9, pp. 2028–2041,
2006.
113.
Y. Wang, D. Botolin, B. Christian, J. Busik, J. Xu, and D. B. Jump, “Tissue-specific, nutritional,
and developmental regulation of rat fatty acid elongases,” Journal of Lipid Research, vol. 46, no.
4, pp. 706–715, 2005.
114.
C. Tang, H. P. Cho, M. T. Nakamura, and S. D. Clarke, “Regulation of human Δ-6 desaturase gene
transcription: identification of a functional direct repeat-1 element,” Journal of Lipid Research,
vol. 44, no. 4, pp. 686–695, 2003.
115.
H. Castelein,  T.  Gulick,  P.  E.  Declercq,  G. P.  Mannaerts,  D. D.  Moore,  and M.  I.  Baes,  “The
peroxisome proliferator activated receptor regulates malic enzyme gene expression,” Journal of
Biological Chemistry, vol. 269, no. 43, pp. 26754–26758, 1994.
116.
C.  W.  Miller  and  J.  M.  Ntambi,  “Peroxisome  proliferators  induce  mouse  liver  stearoyl-CoA
desaturase 1 gene expression,” Proceedings of the National Academy of Sciences of the United
States of America, vol. 93, no. 18, pp. 9443–9448, 1996.
117.
H. Guillou, P. Martin, S. Jan et al., “Comparative effect of fenofibrate on hepatic desaturases in
wild-type and peroxisome proliferator-activated receptor α-deficient mice,” Lipids, vol. 37, no. 10,
pp. 981–989, 2002.
118.
G. F. Gibbons, D. Patel, D. Wiggins, and B. L. Knight, “The functional efficiency of lipogenic and
cholesterogenic  gene  expression  in  normal  mice  and  in  mice  lacking  the  peroxisomal
proliferator-activated receptor-alpha  (PPAR-α),”  Advances in  Enzyme  Regulation,  vol.  42,  pp.
227–247, 2002.
119.
K. T. Dalen, S. M. Ulven, B. M. Arntsen, K. Solaas, and H. I. Nebb, “PPARα activators and fasting
induce  the  expression  of  adipose  differentiation-related  protein  in  liver,”  Journal  of  Lipid
Research, vol. 47, no. 5, pp. 931–943, 2006.
120.
N. Viswakarma, S. Yu, S. Naik  et  al.,  “Transcriptional  regulation  of  Cidea, mitochondrial  cell
death-inducing  DNA  fragmentation  factor  α-like  effector  A,  in  mouse  liver  by  peroxisome
proliferator-activated receptor  α and γ,” Journal of Biological Chemistry, vol. 282, no. 25, pp.
18613–18624, 2007.
121.
X. Yang, X.  Lu,  M.  Lombès et  al.,  “The  G(0)/G(1)  switch  gene  2  regulates adipose  lipolysis
through  association  with  adipose  triglyceride  lipase,”  Cell  Metabolism,  vol.  11,  no.  3,  pp.
194–205, 2010.
122.
F. Zandbergen, S. Mandard, P. Escher et al., “The G0/G1 switch gene 2 is a novel PPAR target
gene,” Biochemical Journal, vol. 392, no. 2, pp. 313–324, 2005.
123.
T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and T. Osumi, “MLDP, a novel PAT family
protein  localized  to  lipid  droplets  and  enriched  in  the  heart,  is  regulated  by  peroxisome
proliferator-activated  receptorα,”  Journal  of  Biological  Chemistry,  vol.  281,  no.  20,  pp.
14232–14240, 2006.
124.
K. T. Dalen, T. Dahl, E. Holter et al., “LSDP5 is a PAT protein specifically expressed in fatty acid
oxidizing tissues,” Biochimica et Biophysica Acta, vol. 1771, no. 2, pp. 210–227, 2007.
125.
S. Kersten, S. Mandard, N. S. Tan et al., “Characterization of the fasting-induced adipose factor
FIAF,  a  novel  peroxisome  proliferator-activated  receptor  target  gene,”  Journal  of  Biological
Chemistry, vol. 275, no. 37, pp. 28488–28493, 2000.
126.
S.  Mandard,  F.  Zandbergen,  N.  S.  Tan  et  al.,  “The  direct  peroxisome  proliferator-activated
receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma
as  a  truncated  protein  that  is  increased  by  fenofibrate  treatment,”  Journal  of  Biological
Chemistry, vol. 279, no. 33, pp. 34411–34420, 2004.
127.
L.  Berthou,  N.  Duverger,  F.  Emmanuel  et  al.,  “Opposite  regulation  of  human  versus mouse
apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice,” Journal of Clinical
128.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
14 van 21 19-8-2011 11:55
Investigation, vol. 97, no. 11, pp. 2408–2416, 1996.
N. Vu-Dac, S. Chopin-Delannoy, P. Gervois et al., “The nuclear receptors peroxisome proliferator-
activated receptor α and rev-erbα mediate the species-specific regulation of apolipoprotein A-I
expression  by  fibrates,”  Journal of  Biological Chemistry,  vol.  273, no.  40, pp.  25713–25720,
1998.
129.
J. M. Peters, N. Hennuyer, B. Staels et al., “Alterations in lipoprotein metabolism in peroxisome
proliferator-activated receptor α-deficient mice,” Journal of Biological Chemistry, vol. 272, no. 43,
pp. 27307–27312, 1997.
130.
N.  Vu-Dac,  K.  Schoonjans,  B.  Laine,  J.-C.  Fruchart,  J.  Auwerx,  and  B.  Staels,  “Negative
regulation  of  the  human  apolipoprotein  A-I  promoter  by  fibrates  can  be  attenuated  by  the
interaction of the peroxisome proliferator-activated receptor with its response element,” Journal
of Biological Chemistry, vol. 269, no. 49, pp. 31012–31018, 1994.
131.
E.  Raspé,  L.  Madsen,  A.-M.  Lefebvre  et  al.,  “Modulation  of  rat  liver  apolipoprotein  gene
expression  and  serum  lipid  levels  by  tetradecylthioacetic  acid  (TTA)  via  PPARα  activation,”
Journal of Lipid Research, vol. 40, no. 11, pp. 2099–2110, 1999.
132.
L. Berthou, R. Saladin, P. Yaqoob et al., “Regulation of rat liver apolipoprotein A-I, apolipoprotein
A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids,” European
Journal of Biochemistry, vol. 232, no. 1, pp. 179–187, 1995.
133.
N.  Vu-Dac,  K.  Schoonjans,  V.  Kosykh  et  al.,  “Fibrates  increase  human  apolipoprotein  A-II
expression  through  activation  of  the  peroxisome  proliferator-activated  receptor,”  Journal  of
Clinical Investigation, vol. 96, no. 2, pp. 741–750, 1995.
134.
X. Prieur, H. Coste, and J. C. Rodríguez, “The human apolipoprotein AV gene is regulated by
peroxisome proliferator-activated receptor-α and contains a novel farnesoid X-activated receptor
response element,” Journal of Biological Chemistry, vol. 278, no. 28, pp. 25468–25480, 2003.
135.
N.  Vu-Dac,  P.  Gervois,  H.  Jakel  et  al.,  “Apolipoprotein  A5,  a  crucial  determinant  of  plasma
triglyceride  levels,  is  highly  responsive  to  peroxisome  proliferator-activated  receptor  α
activators,” Journal of Biological Chemistry, vol. 278, no. 20, pp. 17982–17985, 2003.
136.
R. Hertz, J. Bishara-Shieban, and J. Bar-Tana, “Mode of action of peroxisome proliferators as
hypolipidemic drugs. Suppression of apolipoprotein  C-III,” Journal of Biological Chemistry, vol.
270, no. 22, pp. 13470–13475, 1995.
137.
B. Staels, N. Vu-Dac, V. A. Kosykh et al., “Fibrates downregulate apolipoprotein C-III expression
independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the
hypolipidemic action of fibrates,” Journal of Clinical Investigation, vol. 95, no. 2, pp. 705–712,
1995.
138.
S. Haubenwallner, A. D. Essenburg, B. C. Barnett et al., “Hypolipidemic activity of select fibrates
correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for
their mode of action,” Journal of Lipid Research, vol. 36, no. 12, pp. 2541–2551, 1995.
139.
K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre et al., “PPARα and PPARγ activators direct a
distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” EMBO
Journal, vol. 15, no. 19, pp. 5336–5348, 1996.
140.
M.  Bouly,  D.  Masson,  B.  Gross  et  al.,  “Induction  of  the  phospholipid  transfer  protein  gene
accounts for the high density lipoprotein enlargement in mice treated with fenofibrate,” Journal
of Biological Chemistry, vol. 276, no. 28, pp. 25841–25847, 2001.
141.
A.-Y.  Tu  and  J.  J.  Albers,  “Functional  analysis  of  the  transcriptional  activity  of  the  mouse
phospholipid transfer protein gene,” Biochemical and Biophysical Research Communications, vol.
287, no. 4, pp. 921–926, 2001.
142.
N.  J.  Spann,  S.  Kang,  A.  C.  Li  et  al.,  “Coordinate  transcriptional  repression  of  liver  fatty
acid-binding protein and microsomal triglyceride transfer protein blocks hepatic very low density
lipoprotein secretion without hepatosteatosis,” Journal of Biological Chemistry, vol. 281, no. 44,
pp. 33066–33077, 2006.
143.
T. Kok, H. Wolters, V. W. Bloks et al., “Induction of hepatic ABC transporter expression is part of
the  PPARα-mediated fasting response  in  the  mouse,”  Gastroenterology,  vol.  124,  no.  1,  pp.
160–171, 2003.
144.
S. M. Post, H. Duez, P. P. Gervois, B. Staels, F. Kuipers, and H. M. G. Princen, “Fibrates suppress
bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of
cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 21, no. 11, pp. 1840–1845, 2001.
145.
D. D. Patel, B. L. Knight, A. K. Soutar, G. F. Gibbons, and D. P. Wade, “The effect of peroxisome-
proliferator-activated  receptor-α  on  the  activity  of  the  cholesterol  7α-hydroxylase  gene,”
Biochemical Journal, vol. 351, no. 3, pp. 747–753, 2000.
146.
S.  K.  Cheema and L.  B.  Agellon,  “The  murine  and human  cholesterol  7α-hydroxylase  gene
promoters are  differentially  responsive  to  regulation  by  fatty  acids mediated via  peroxisome
proliferator-activated  receptor  α,”  Journal  of  Biological  Chemistry,  vol.  275,  no.  17,  pp.
147.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
15 van 21 19-8-2011 11:55
12530–12536, 2000.
M. C. Hunt, Y.-Z. Yang, G. Eggertsen et al., “The peroxisome proliferator-activated receptor  α
(PPARα) regulates bile acid biosynthesis,” Journal of Biological Chemistry, vol. 275, no. 37, pp.
28947–28953, 2000.
148.
K. A. R. Tobin, H. H. Steineger, S. Albert et al., “Cross-talk between fatty acid and cholesterol
metabolism  mediated  by  liver  X  receptor-α,”  Molecular  Endocrinology,  vol.  14,  no.  5,  pp.
741–752, 2000.
149.
D. Jung, M. Fried, and G. A. Kullak-Ublick, “Human apical sodium-dependent bile salt transporter
gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor  α,”  Journal of
Biological Chemistry, vol. 277, no. 34, pp. 30559–30566, 2002.
150.
D. Patsouris, S. Mandard, P. J. Voshol  et al., “PPARα governs glycerol  metabolism,” Journal of
Clinical Investigation, vol. 114, no. 1, pp. 94–103, 2004.
151.
S.  Mandard,  R.  Stienstra,  P.  Escher  et  al.,  “Glycogen  synthase  2  is  a  novel  target  gene  of
peroxisome proliferator-activated receptors,” Cellular and Molecular Life Sciences, vol. 64, no. 9,
pp. 1145–1157, 2007.
152.
M.  C.  Sugden,  K.  Bulmer,  G.  F.  Gibbons,  B.  L.  Knight,  and  M.  J.  Holness,  “Peroxisome-
proliferator-activated receptor-α (PPARα) deficiency leads to dysregulation of hepatic lipid and
carbohydrate metabolism by fatty acids and insulin,” Biochemical Journal, vol. 364, no. 2, pp.
361–368, 2002.
153.
P. Wu, J. M. Peters, and R. A. Harris, “Adaptive increase in pyruvate dehydrogenase kinase 4
during starvation is mediated by peroxisome proliferator-activated receptor α,” Biochemical and
Biophysical Research Communications, vol. 287, no. 2, pp. 391–396, 2001.
154.
J.  C.  Corton,  L.-Q.  Fan,  S.  Brown  et  al.,  “Down-regulation  of  cytochrome  P450  2C  family
members  and  positive  acute-phase  response  gene  expression  by  peroxisome  proliferator
chemicals,” Molecular Pharmacology, vol. 54, no. 3, pp. 463–473, 1998.
155.
M. Arand, M. W. H. Coughtrie, B. Burchell, F. Oesch, and L. W. Robertson, “Selective induction of
bilirubin  UDP-glucuronosyl-transferase  by  perfluorodecanoic  acid,”  Chemico-Biological
Interactions, vol. 77, no. 1, pp. 97–105, 1991.
156.
A. Foliot and P. Beaune, “Effects of microsomal enzyme inducers on glutathione S-transferase
isoenzymes  in  livers  of  rats  and  hamsters,”  Biochemical  Pharmacology,  vol.  48,  no.  2,  pp.
293–300, 1994.
157.
O. Barbier, L. Villeneuve, V. Bocher et al., “The UDP-glucuronosyltransferase 1A9 enzyme is a
peroxisome proliferator-activated receptor α and γ target gene,” Journal of Biological Chemistry,
vol. 278, no. 16, pp. 13975–13983, 2003.
158.
K. Sheikh, G. Camejo, B. Lanne, T. Halvarsson, M. R. Landergren, and N. D. Oakes, “Beyond
lipids,  pharmacological  PPARα  activation  has important  effects on  amino acid  metabolism as
studied in the rat,” American Journal of Physiology, vol. 292, no. 4, pp. E1157–E1165, 2007.
159.
S.  Kersten,  S.  Mandard,  P.  Escher  et  al.,  “The  peroxisome  proliferator-activated  receptor  α
regulates amino acid metabolism,” FASEB Journal, vol. 15, no. 11, pp. 1971–1978, 2001.
160.
A. D. Edgar, C. Tomkiewicz, P. Costet et al., “Fenofibrate modifies transaminase gene expression
via a peroxisome proliferator activated receptor α-dependent pathway,” Toxicology Letters, vol.
98, no. 1-2, pp. 13–23, 1998.
161.
L.  Makowski,  R.  C.  Noland, T.  R.  Koves et  al.,  “Metabolic  profiling of  PPARα-/-  mice  reveals
defects in  carnitine and amino acid homeostasis that  are  partially  reversed by oral  carnitine
supplementation,” FASEB Journal, vol. 23, no. 2, pp. 586–604, 2009.
162.
R. Stienstra, S. Mandard, N. S. Tan et al., “The Interleukin-1  receptor  antagonist  is a direct
target gene of PPARα in liver,” Journal of Hepatology, vol. 46, no. 5, pp. 869–877, 2007.
163.
R. Kleemann, P. P. Gervois, L. Verschuren, B. Staels, H. M. G. Princen, and T. Kooistra, “Fibrates
down-regulate IL-1-stimulated C-reactive  protein  gene expression  in  hepatocytes by  reducing
nuclear p50-NFκB-C/EBP-β complex formation,” Blood, vol. 101, no. 2, pp. 545–551, 2003.
164.
R.  Stienstra,  S.  Mandard,  D.  Patsouris,  C.  Maass,  S.  Kersten,  and  M.  Müller,  “Peroxisome
proliferator-activated  receptor  α  protects  against  obesity-induced  hepatic  inflammation,”
Endocrinology, vol. 148, no. 6, pp. 2753–2763, 2007.
165.
P.  Gervois,  N.  Vu-Dac,  R.  Kleemann  et  al.,  “Negative  regulation  of  human  fibrinogen  gene
expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT
box/enhancer-binding  protein  beta,”  Journal  of  Biological  Chemistry,  vol.  276,  no.  36,  pp.
33471–33477, 2001.
166.
M. Kockx, P. P. Gervois, P. Poulain et al., “Fibrates suppress fibrinogen gene expression in rodents
via  activation  of  the  peroxisome proliferator-activated receptor-α,”  Blood,  vol.  93,  no.  9, pp.
2991–2998, 1999.
167.
P. Delerive, K. De Bosscher, W. V. Berghe, J.-C. Fruchart, G. Haegeman, and B. Staels, “DNA
binding-independent induction  of IκBα gene transcription by PPARα,” Molecular  Endocrinology,
168.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
16 van 21 19-8-2011 11:55
vol. 16, no. 5, pp. 1029–1039, 2002.
P.  Delerive,  P.  Gervois,  J.-C.  Fruchart,  and  B.  Staels,  “Induction  of  IκBα  expression  as  a
mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated
receptor-α activators,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000.
169.
W. Vanden Berghe, L. Vermeulen, P. Delerive, K. De Bosscher, B. Staels, and G. Haegeman, “A
paradigm  for  gene  regulation:  inflammation,  NF-κB  and  PPAR,”  Advances  in  Experimental
Medicine and Biology, vol. 544, pp. 181–196, 2003.
170.
P.  Gervois,  R.  Kleemann,  A.  Pilon  et  al.,  “Global  suppression  of  IL-6-induced  acute  phase
response  gene  expression  after  chronic  in  vivo  treatment  with  the  peroxisome  proliferator-
activated receptor-alpha activator fenofibrate,” Journal of Biological Chemistry, vol. 279, no. 16,
pp. 16154–16160, 2004.
171.
C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal
β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp.
879–887, 1992.
172.
J. E. Klaunig, M. A. Babich, K. P. Baetcke et al., “PPARα agonist-induced rodent tumors: modes of
action and human relevance,” Critical Reviews in Toxicology, vol. 33, no. 6, pp. 655–780, 2003.
173.
J.  W.  Lawrence,  Y.  Li,  S.  Chen  et  al.,  “Differential  gene  regulation  in  human  versus rodent
hepatocytes  by  peroxisome  proliferator-activated  receptor  (PPAR)  α.  PPARα  fails  to  induce
peroxisome proliferation-associated genes in human cells independently of the level of receptor
expression,” Journal of Biological Chemistry, vol. 276, no. 34, pp. 31521–31527, 2001.
174.
N. Roglans, A. Bellido, C. Rodríguez et al., “Fibrate treatment does not modify the expression of
acyl coenzyme A oxidase in human liver,” Clinical Pharmacology and Therapeutics, vol. 72, no. 6,
pp. 692–701, 2002.
175.
T. Hashimoto, W. S. Cook, C. Qi, A. V. Yeldandi, J. K. Reddy, and M. S. Rao, “Defect in peroxisome
proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic
steatosis  in  response  to  fasting,”  Journal  of  Biological  Chemistry,  vol.  275,  no.  37,  pp.
28918–28928, 2000.
176.
F. E. Frerman, “Acyl-CoA dehydrogenases, electron transfer  flavoprotein and electron transfer
flavoprotein  dehydrogenase,”  Biochemical  Society  Transactions,  vol.  16,  no.  3,  pp.  416–418,
1988.
177.
J. D. Beckmann  and F. E. Frerman, “Electron-transfer  flavoprotein-ubiquinone oxidoreductase
from pig liver: purification and molecular, redox, and catalytic properties,” Biochemistry, vol. 24,
no. 15, pp. 3913–3921, 1985.
178.
P.  Honkakoski  and  M.  Negishi,  “Regulation  of  cytochrome  P450  (CYP)  genes  by  nuclear
receptors,” Biochemical Journal, vol. 347, no. 2, pp. 321–337, 2000.
179.
E. F. Johnson, M.-H. Hsu, U. Savas, and K. J.  Griffin, “Regulation  of P450  4A  expression  by
peroxisome proliferator activated receptors,” Toxicology, vol. 181-182, pp. 203–206, 2002.
180.
R. C.  Cattley,  J.  DeLuca, C.  Elcombe  et  al.,  “Do peroxisome proliferating compounds pose  a
hepatocarcinogenic hazard to humans?” Regulatory Toxicology and Pharmacology, vol. 27, no. 1,
part 1, pp. 47–60, 1998.
181.
L. A. Cowart, S. Wei, M.-H. Hsu et al., “The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids
to  form high  affinity  peroxisome proliferator-activated receptor  ligands,”  Journal of  Biological
Chemistry, vol. 277, no. 38, pp. 35105–35112, 2002.
182.
M. H. Oosterveer, A. Grefhorst, T. H. van Dijk et al., “Fenofibrate simultaneously induces hepatic
fatty acid oxidation, synthesis, and elongation in mice,” Journal of Biological Chemistry, vol. 284,
no. 49, pp. 34036–34044, 2009.
183.
Y. Takeuchi, N. Yahagi, Y. Izumida et al., “Polyunsaturated fatty acids selectively suppress sterol
regulatory  element-binding protein-1  through  proteolytic  processing and autoloop regulatory
circuit,” Journal of Biological Chemistry, vol. 285, no. 15, pp. 11681–11691, 2010.
184.
B. König, A. Koch, J. Spielmann et al., “Activation of PPARα and PPARγ reduces triacylglycerol
synthesis  in  rat  hepatoma  cells  by  reduction  of  nuclear  SREBP-1,”  European  Journal  of
Pharmacology, vol. 605, no. 1–3, pp. 23–30, 2009.
185.
E.  Soupene  and F.  A.  Kuypers,  “Mammalian  long-chain  acyl-CoA  synthetases,”  Experimental
Biology and Medicine, vol. 233, no. 5, pp. 507–521, 2008.
186.
I. Issemann, R. Prince, J. Tugwood, and S. Green, “A role for  fatty acids and liver  fatty acid
binding protein in peroxisome proliferation?” Biochemical Society Transactions, vol. 20, no. 4, pp.
824–827, 1992.
187.
T. C. Simon, K. A. Roth, and J. I. Gordon, “Use of transgenic mice to map cis-acting elements in
the  liver  fatty  acid-  binding  protein  gene  (Fabpl)  that  regulate  its  cell  lineage-specific,
differentiation-dependent, and spatial  patterns of expression in the gut epithelium and in the
liver acinus,” Journal of Biological Chemistry, vol. 268, no. 24, pp. 18345–18358, 1993.
188.
J. Storch and L. McDermott, “Structural and functional analysis of fatty acid-binding proteins,”189.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
17 van 21 19-8-2011 11:55
Journal of Lipid Research, vol. 50, pp. S126–S131, 2009.
S. Yu,  K. Matsusue, P.  Kashireddy  et  al.,  “Adipocyte-specific  gene  expression  and adipogenic
steatosis  in  the  mouse  liver  due  to  peroxisome  proliferator-activated  receptor  γ1  (PPARγ1)
overexpression,” Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003.
190.
P. Costet, C. Legendre, J. Moré, A. Edgar, P. Galtier, and T. Pineau, “Peroxisome proliferator-
activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic
obesity and steatosis,” Journal of Biological Chemistry, vol. 273, no. 45, pp. 29577–29585, 1998.
191.
J. K. Reddy, “Nonalcoholic steatosis and steatohepatitis III. Peroxisomal β-oxidation, PPARα, and
steatohepatitis,” American Journal of Physiology, vol. 281, no. 6, pp. G1333–G1339, 2001.
192.
C. Fernández-Miranda, M. Pérez-Carreras, F. Colina, G. López-Alonso, C. Vargas, and J. A. Solís-
Herruzo,  “A  pilot  trial  of  fenofibrate  for  the  treatment  of  non-alcoholic  fatty  liver  disease,”
Digestive and Liver Disease, vol. 40, no. 3, pp. 200–205, 2008.
193.
S.  Kersten,  “Peroxisome  proliferator  activated  receptors  and  lipoprotein  metabolism,”  PPAR
Research, vol. 2008, Article ID 132960, 11 pages, 2008.
194.
B. N. Reid, G. P. Ables, O. A. Otlivanchik et al., “Hepatic overexpression of hormone-sensitive
lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of
free fatty acids, and ameliorates steatosis,” Journal of Biological Chemistry, vol. 283, no. 19, pp.
13087–13099, 2008.
195.
R.  Zimmermann,  J.  G.  Strauss,  G.  Haemmerle  et  al.,  “Fat  mobilization  in  adipose  tissue  is
promoted by adipose triglyceride lipase,” Science, vol. 306, no. 5700, pp. 1383–1386, 2004.
196.
G. Haemmerle, R. Zimmermann, M. Hayn et al., “Hormone-sensitive lipase deficiency in mice
causes  diglyceride  accumulation  in  adipose  tissue,  muscle,  and  testis,”  Journal  of  Biological
Chemistry, vol. 277, no. 7, pp. 4806–4815, 2002.
197.
C. M. Jenkins, D. J. Mancuso, W. Yan, H. F. Sims, B. Gibson, and R. W. Gross, “Identification,
cloning, expression, and purification of three novel human calcium-independent phospholipase
A2  family  members possessing triacylglycerol  lipase  and acylglycerol  transacylase  activities,”
Journal of Biological Chemistry, vol. 279, no. 47, pp. 48968–48975, 2004.
198.
S. He, C. McPhaul, J. Z. Li  et  al., “A  sequence variation  (I148M) in  PNPLA3 associated with
nonalcoholic fatty liver disease disrupts triglyceride hydrolysis,” Journal of Biological Chemistry,
vol. 285, no. 9, pp. 6706–6715, 2010.
199.
Y. Huang, S. He, J. Z. Li et al., “A feed-forward loop amplifies nutritional regulation of PNPLA3,”
Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no.
17, pp. 7892–7897, 2010.
200.
T. Deng, S. Shan, P.-P. Li  et al., “Peroxisome proliferator-activated receptor-γ  transcriptionally
up-regulates  hormone-sensitive  lipase  via  the  involvement  of  specificity  protein-1,”
Endocrinology, vol. 147, no. 2, pp. 875–884, 2006.
201.
J. Y. Kim, K. Tillison, J.-H. Lee, D. A. Rearick, and C. M. Smas, “The adipose tissue triglyceride
lipase ATGL/PNPLA2 is downregulated by insulin and TNF-α in 3T3-L1 adipocytes and is a target
for transactivation by PPARγ,” American Journal of Physiology, vol. 291, no. 1, pp. E115–E127,
2006.
202.
B. Magnusson, L. Asp, P. Boström et al., “Adipocyte differentiation-related protein promotes fatty
acid storage  in  cytosolic triglycerides and inhibits secretion  of  very  low-density  lipoproteins,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1566–1571, 2006.
203.
K. T. Dalen, K. Schoonjans, S. M. Ulven et al., “Adipose tissue expression of the lipid droplet-
associating  proteins  S3-12  and  perilipin  is  controlled  by  peroxisome  proliferator-activated
receptor-γ,” Diabetes, vol. 53, no. 5, pp. 1243–1252, 2004.
204.
B. K. Straub, P. Stoeffel, H. Heid, R. Zimbelmann, and P. Schirmacher, “Differential  pattern of
lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis,”
Hepatology, vol. 47, no. 6, pp. 1936–1946, 2008.
205.
V. Puri, S. Konda, S. Ranjit  et  al., “Fat-specific protein  27, a novel  lipid droplet  protein  that
enhances  triglyceride  storage,”  Journal  of  Biological  Chemistry,  vol.  282,  no.  47,  pp.
34213–34218, 2007.
206.
V. Puri, S. Ranjit, S. Konda et al., “Cidea is associated with lipid droplets and insulin sensitivity in
humans,” Proceedings of the National Academy of Sciences of the United States of America, vol.
105, no. 22, pp. 7833–7838, 2008.
207.
Y.-J. Kim, S. Y. Cho, C. H. Yun, Y. S. Moon, T. R. Lee, and S. H. Kim, “Transcriptional activation of
Cidec by PPARγ2 in adipocyte,” Biochemical and Biophysical Research Communications, vol. 377,
no. 1, pp. 297–302, 2008.
208.
K.  Matsusue,  T.  Kusakabe,  T.  Noguchi  et  al.,  “Hepatic  steatosis  in  leptin-deficient  mice  is
promoted by the PPARgamma target gene Fsp27,” Cell Metabolism, vol. 7, no. 4, pp. 302–311,
2008.
209.
M.  H.  Frick,  O.  Elo,  and  K.  Haapa,  “Helsinki  Heart  Study:  primary-prevention  trial  with210.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
18 van 21 19-8-2011 11:55
gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors,
and incidence of coronary heart disease,” The New England Journal of Medicine, vol. 317, no. 20,
pp. 1237–1245, 1987.
H. B. Rubins, S. J. Robins, D. Collins et al., “Gemfibrozil for the secondary prevention of coronary
heart disease in men with low levels of high-density lipoprotein cholesterol,” The New England
Journal of Medicine, vol. 341, no. 6, pp. 410–418, 1999.
211.
S. Behar, D. Brunner, E. Kaplinsky, L. Mandelzweig, and M. Benderly, “Secondary prevention by
raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the
bezafibrate infarction prevention (BIP) study,” Circulation, vol. 102, no. 1, pp. 21–27, 2000.
212.
G. Steiner, A. Hamsten, J. Hosking et al., “Effect of fenofibrate on progression of coronary-artery
disease  in  type  2  diabetes:  the  Diabetes  Atherosclerosis  Intervention  Study,  a  randomised
study,” The Lancet, vol. 357, no. 9260, pp. 905–910, 2001.
213.
C. Améen, U. Edvardsson, A. Ljungberg et al., “Activation of peroxisome proliferator-activated
receptor α increases the expression and activity of microsomal triglyceride transfer protein in the
liver,” Journal of Biological Chemistry, vol. 280, no. 2, pp. 1224–1229, 2005.
214.
L.  Camps,  M.  Reina,  M.  Llobera,  G.  Bengtsson-Olivecrona,  T.  Olivecrona,  and  S.  Vilaro,
“Lipoprotein  lipase  in  lungs,  spleen,  and  liver:  synthesis  and  distribution,”  Journal  of  Lipid
Research, vol. 32, no. 12, pp. 1877–1888, 1991.
215.
R.  Carroll  and  D.  L.  Severson,  “Peroxisome  proliferator-activated  receptor-α  ligands  inhibit
cardiac  lipoprotein  lipase  activity,”  American  Journal  of  Physiology,  vol.  281,  no.  2,  pp.
H888–H894, 2001.
216.
E. Raspé, H. Duez, A. Mansén et al., “Identification of Rev-erbα as a physiological repressor of
apoC-III gene transcription,” Journal of Lipid Research, vol. 43, no. 12, pp. 2172–2179, 2002.
217.
P. Gervois, S. Chopin-Delannoy, A. Fadel et al., “Fibrates increase human REV-ERBα expression
in  liver  via  a  novel  peroxisome  proliferator-activated  receptor  response  element,”  Molecular
Endocrinology, vol. 13, no. 3, pp. 400–409, 1999.
218.
S.  Qu,  D.  Su,  J.  Altomonte  et  al.,  “PPARα  mediates the  hypolipidemic  action  of  fibrates by
antagonizing FoxO1,” American Journal of Physiology, vol. 292, no. 2, pp. E421–E434, 2007.
219.
A. E. Schultze, W. E. Alborn, R. K. Newton, and R. J. Konrad, “Administration of a PPARα agonist
increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio,”
Journal of Lipid Research, vol. 46, no. 8, pp. 1591–1595, 2005.
220.
H. Tao, S. Aakula, N. N. Abumrad, and T. Hajri, “Peroxisome proliferator-activated receptor-γ
regulates the expression and function of very-low-density lipoprotein receptor,” American Journal
of Physiology, vol. 298, no. 1, pp. E68–E79, 2010.
221.
J.-M. Bard, H.-J. Parra, R. Camare et al., “A multicenter comparison of the effects of simvastatin
and fenofibrate therapy in  severe primary  hypercholesterolemia, with  particular  emphasis on
lipoproteins  defined  by  their  apolipoprotein  composition,”  Metabolism,  vol.  41,  no.  5,  pp.
498–503, 1992.
222.
S.  Lussier-Cacan,  J.-M.  Bard,  L.  Boulet  et  al.,  “Lipoprotein  composition  changes  induced by
fenofibrate in dysbetalipoproteinemia type III,” Atherosclerosis, vol. 78, no. 2-3, pp. 167–182,
1989.
223.
H.  Duezt,  Y.-S.  Chao,  M.  Hernandez  et  al.,  “Reduction  of  atherosclerosis  by  the  peroxisome
proliferator-activated receptor α agonist fenofibrate in mice,” Journal of Biological Chemistry, vol.
277, no. 50, pp. 48051–48057, 2002.
224.
B. Staels, A. Van Tol, T. Andreu, and J. Auwerx, “Fibrates influence the expression  of genes
involved in lipoprotein metabolism in a tissue-selective manner in the rat,” Arteriosclerosis and
Thrombosis, vol. 12, no. 3, pp. 286–294, 1992.
225.
L. M. Sanderson, M. V. Boekschoten, B. Desvergne, M. Müller, and S. Kersten, “Transcriptional
profiling reveals  divergent  roles  of  PPARα  and PPARβ/δ  in  regulation  of  gene  expression  in
mouse liver,” Physiological Genomics, vol. 41, no. 1, pp. 42–52, 2010.
226.
T. Ishida, S. Choi, R. K. Kundu et al., “Endothelial lipase is a major determinant of HDL level,”
Journal of Clinical Investigation, vol. 111, no. 3, pp. 347–355, 2003.
227.
W. Jin, J. S. Millar, U. Broedl, J. M. Glick, and D. J. Rader, “Inhibition of endothelial lipase causes
increased HDL cholesterol  levels in vivo,” Journal of Clinical Investigation, vol. 111, no. 3, pp.
357–362, 2003.
228.
U. C. Broedl, C. Maugeais, D. Marchadier, J. M. Glick, and D. J. Rader, “Effects of nonlipolytic
ligand function of endothelial lipase on high density lipoprotein metabolism in vivo,” Journal of
Biological Chemistry, vol. 278, no. 42, pp. 40688–40693, 2003.
229.
J.-P.  Desager,  Y.  Horsmans,  C.  Vandenplas,  and  C.  Harvengt,  “Pharmacodynamic  activity  of
lipoprotein  lipase  and  hepatic  lipase,  and  pharmacokinetic  parameters  measured  in
normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or  micronised fenofibrate
(200 mg/day) therapy for 23 days,” Atherosclerosis, vol. 124, supplement, pp. S65–S73, 1996.
230.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
19 van 21 19-8-2011 11:55
H. W. Kang, K. Kanno, E. F. Scapa, and D. E. Cohen, “Regulatory role for phosphatidylcholine
transfer protein/StarD2 in the metabolic response to peroxisome proliferator activated receptor
alpha (PPARα),” Biochimica et Biophysica Acta, vol. 1801, no. 4, pp. 496–502, 2010.
231.
S.  Jitrapakdee,  M.  Slawik,  G.  Medina-Gomez  et  al.,  “The  peroxisome  proliferator-activated
receptor-γ regulates murine pyruvate carboxylase gene expression in vivo and in vitro,” Journal
of Biological Chemistry, vol. 280, no. 29, pp. 27466–27476, 2005.
232.
M. C. Sugden, K. Bulmer, G. F. Gibbons, and M. J. Holness, “Role of peroxisome proliferator-
activated receptor-α  in  the  mechanism underlying changes in  renal  pyruvate  dehydrogenase
kinase isoform 4 protein expression in starvation and after refeeding,” Archives of Biochemistry
and Biophysics, vol. 395, no. 2, pp. 246–252, 2001.
233.
P. Wu, K. Inskeep, M. M. Bowker-Kinley, K. M. Popov, and R. A. Harris, “Mechanism responsible
for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes,”
Diabetes, vol. 48, no. 8, pp. 1593–1599, 1999.
234.
M.  J.  Holness,  K.  Bulmer,  G.  F.  Gibbons,  and  M.  C.  Sugden,  “Up-regulation  of  pyruvate
dehydrogenase kinase isoform 4 (PDK4) protein expression in oxidative skeletal muscle does not
require  the  obligatory  participation  of  peroxisome-proliferator-activated  receptor  α  (PPARα),”
Biochemical Journal, vol. 366, no. 3, pp. 839–846, 2002.
235.
M. J. Holness, N. D. Smith, K. Bulmer, T. Hopkins, G. F. Gibbons, and M. C. Sugden, “Evaluation
of the role of peroxisome-proliferator-activated receptor α in the regulation of cardiac pyruvate
dehydrogenase  kinase  4  protein  expression  in  response  to  starvation,  high-fat  feeding  and
hyperthyroidism,” Biochemical Journal, vol. 364, no. 3, pp. 687–694, 2002.
236.
B.  L.  Knight,  D.  D.  Patel,  S.  M.  Humphreys,  D.  Wiggins,  and  G.  F.  Gibbons,  “Inhibition  of
cholesterol  absorption  associated  with  a  PPARα-dependent  increase  in  ABC  binding  cassette
transporter A1 in mice,” Journal of Lipid Research, vol. 44, no. 11, pp. 2049–2058, 2003.
237.
D. Stahlberg, B. Angelin, and K. Einarsson, “Effects of treatment with clofibrate, bezafibrate, and
ciprofibrate on the metabolism of cholesterol in rat liver microsomes,” Journal of Lipid Research,
vol. 30, no. 7, pp. 953–958, 1989.
238.
D. Ståhlberg, E. Reihnér, M. Rudling, L. Berglund, K. Einarsson, and B. O. Angelin, “Influence of
bezafibrate  on  hepatic  cholesterol  metabolism  in  gallstone  patients:  reduced  activity  of
cholesterol 7α-hydroxylase,” Hepatology, vol. 21, no. 4, pp. 1025–1030, 1995.
239.
M. Bertolotti, M. Concari, P. Loria et al., “Effects of different phenotypes of hyperlipoproteinemia
and of  treatment  with  fibric  acid derivatives on  the  rates of  cholesterol  7α-hydroxylation  in
humans,”  Arteriosclerosis,  Thrombosis,  and Vascular  Biology,  vol.  15,  no.  8,  pp.  1064–1069,
1995.
240.
K. S. Miyata, S. E. McCaw, H. V. Patel, R. A. Rachubinski, and J. P. Capone, “The orphan nuclear
hormone receptor LXRα interacts with the peroxisome proliferator-activated receptor and inhibits
peroxisome  proliferator  signaling,”  Journal  of  Biological  Chemistry,  vol.  271,  no.  16,  pp.
9189–9192, 1996.
241.
T. Yoshikawa, T. Ide, H. Shimano et al., “Cross-talk between peroxisome proliferator-activated
receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I.
PPARS suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR
signaling,” Molecular Endocrinology, vol. 17, no. 7, pp. 1240–1254, 2003.
242.
G. F. Gbaguidi and L. B. Agellon, “The atypical interaction of peroxisome proliferator-activated
receptor α with liver X receptor α antagonizes the stimulatory effect of their respective ligands
on the murine cholesterol  7α-hydroxylase gene promoter,” Biochimica et Biophysica Acta, vol.
1583, no. 2, pp. 229–236, 2002.
243.
N. Leuenberger, S. Pradervand, and W. Wahli, “Sumoylated PPARα mediates sex-specific gene
repression  and protects the  liver  from estrogen-induced toxicity  in  mice,”  Journal of  Clinical
Investigation, vol. 119, no. 10, pp. 3138–3148, 2009.
244.
M. W. Walters and K. B. Wallace, “Urea cycle gene expression is suppressed by PFOA treatment
in rats,” Toxicology Letters, vol. 197, no. 1, pp. 46–50, 2010.
245.
P.  Thulin,  I.  Rafter,  K.  Stockling et  al.,  “PPARα  regulates the  hepatotoxic  biomarker  alanine
aminotransferase  (ALT1)  gene  expression  in  human  hepatocytes,”  Toxicology  and  Applied
Pharmacology, vol. 231, no. 1, pp. 1–9, 2008.
246.
P.  Delerive,  K.  De  Bosscher,  S.  Besnard et  al.,  “Peroxisome proliferator-activated receptor  α
negatively  regulates  the  vascular  inflammatory  gene  response  by  negative  cross-talk  with
transcription  factors NF-κB  and AP-1,”  Journal of  Biological Chemistry,  vol.  274, no.  45, pp.
32048–32054, 1999.
247.
P.  Delerive,  J.-C.  Fruchart,  and  B.  Staels,  “Peroxisome  proliferator-activated  receptors  in
inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001.
248.
B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited
by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998.
249.
A. Madej, B. Okopien, J. Kowalski et al., “Effects of fenofibrate on plasma cytokine concentrations250.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
20 van 21 19-8-2011 11:55
in  patients with  atherosclerosis and hyperlipoproteinemia IIb,” International Journal of Clinical
Pharmacology and Therapeutics, vol. 36, no. 6, pp. 345–349, 1998.
F.  Martin,  M.-F.  Penet,  F.  Malergue  et  al.,  “Vanin-1-/-  mice  show  decreased  NSAID-  and
Schistosoma-induced intestinal inflammation associated with higher gluthathione stores,” Journal
of Clinical Investigation, vol. 113, no. 4, pp. 591–597, 2004.
251.
C. Berruyer, L. Pouyet, V. Millet et al., “Vanin-1 licenses inflammatory mediator production by
gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor
γ activity,” Journal of Experimental Medicine, vol. 203, no. 13, pp. 2817–2827, 2006.
252.
L. Pouyet, C. Roisin-Bouffay, A. Clément et al., “Epithelial vanin-1 controls inflammation-driven
carcinogenesis in the colitis-associated colon cancer model,” Inflammatory Bowel Diseases, vol.
16, no. 1, pp. 96–104, 2010.
253.
E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, “Central  role of PPARα-
dependent hepatic lipid turnover in dietary steatohepatitis in mice,” Hepatology, vol. 38, no. 1,
pp. 123–132, 2003.
254.
E. Ip, G. Farrell,  P. Hall,  G. Robertson, and I.  Leclercq, “Administration  of the  potent  PPARα
agonist, Wy-14,643, reverses nutritional  fibrosis and steatohepatitis in mice,” Hepatology, vol.
39, no. 5, pp. 1286–1296, 2004.
255.
P. V. Kashireddy and M. S. Rao, “Lack of peroxisome proliferator-activated receptor α in mice
enhances methionine and choline deficient diet-induced steatohepatitis,” Hepatology Research,
vol. 30, no. 2, pp. 104–110, 2004.
256.
R.  Shiri-Sverdlov,  K.  Wouters,  P.  J.  V.  Gorp  et  al.,  “Early  diet-induced  non-alcoholic
steatohepatitis in APOE2 knock-in mice and its prevention by fibrates,” Journal of Hepatology,
vol. 44, no. 4, pp. 732–741, 2006.
257.
T. Nakajima, Y. Kamijo, N. Tanaka et al., “Peroxisome proliferator-activated receptor α protects
against alcohol-induced liver damage,” Hepatology, vol. 40, no. 4, pp. 972–980, 2004.
258.
L.  Romics  Jr.,  K.  Kodys,  A.  Dolganiuc  et  al.,  “Diverse  regulation  of  NF-κB  and  peroxisome
proliferator-activated receptors in murine nonalcoholic fatty liver,” Hepatology, vol. 40, no. 2, pp.
376–385, 2004.
259.
J.  Yu,  E.  Ip,  A.  Dela  Peña  et  al.,  “COX-2  induction  in  mice  with  experimental  nutritional
steatohepatitis: role as pro-inflammatory mediator,” Hepatology, vol. 43, no. 4, pp. 826–836,
2006.
260.
T. H. Rushmore and A.-N. T. Kong, “Pharmacogenomics, regulation  and signaling pathways of
phase  I  and  II  drug  metabolizing  enzymes,”  Current  Drug  Metabolism,  vol.  3,  no.  5,  pp.
481–490, 2002.
261.
K.  W.  Bock,  “Vertebrate  UDP-glucuronosyltransferases:  functional  and  evolutionary  aspects,”
Biochemical Pharmacology, vol. 66, no. 5, pp. 691–696, 2003.
262.
J. König, A. T. Nies, Y. Cui, I. Leier, and D. Keppler, “Conjugate export pumps of the multidrug
resistance  protein  (MRP)  family:  localization,  substrate  specificity,  and  MRP2-mediated  drug
resistance,” Biochimica et Biophysica Acta, vol. 1461, no. 2, pp. 377–394, 1999.
263.
I. Voskoboinik, R. Drew, and J. T. Ahokas, “Differential effect of peroxisome proliferators on rat
glutathione S-transferase isoenzymes,” Toxicology Letters, vol. 87, no. 2-3, pp. 147–155, 1996.
264.
S.  I.  James  and  J.  T.  Ahokas,  “Effect  of  peroxisome  proliferators  on  glutathione-dependent
sulphobromophthalein excretion,” Xenobiotica, vol. 22, no. 12, pp. 1425–1432, 1992.
265.
Peroxisome Proliferator-Activated Receptor Alpha Target Genes http://www.hindawi.com/journals/ppar/2010/612089/
21 van 21 19-8-2011 11:55
